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SUMMARY
Diabetic autonomic neuropathy is the most commonly- 
occurring form of autonomic nervous system dysfunction 
found in clinical practice. Despite the difficulties 
encountered in studying single control mechanisms in the 
presence of this disease (Introduction), it may be 
possible to elucidate information on physiological control 
of some dynamic aspects of cardiovascular and 
neuroendocrine influences by looking at a group of 
severely affected diabetics and their responses.
The aims of this thesis (Chapter 1.4) were to examine 
certain aspects of Beta-adrenoreceptor function and 
physiology of arginine vasopressin and its effects in a 
group of diabetics with cardiovascular reflex test 
evidence of autonomic neuropathy. By comparing and 
contrasting these results with the existing literature in 
both diabetes and other forms of autonomic dysfunction, 
conclusions about denervation in diabetes might be 
reached.
Chapter 1 provides the background to the studies presented 
in chapters 3 - 6 .  An historical background to the 
discovery of, and the importance of autonomic neuropathy 
in diabetes is considered, along with sections addressing 
the clinical features and natural history of the disease
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(Chapter 1.1.1 - 1.1.3). There follows a section on 
neural control of the heart, with special reference to the 
anatomy, physiological effects of afferent inputs and 
sympathetic/parasympathetic interactions within the heart. 
The physiological control of the heart in denervation is 
also considered (Chapter 1.2.1 - 1.2.4). In order to 
illustrate the study presented in chapter 3, I provide a 
background to beta-adrenoreceptors, beta-adrenoreceptor 
blocking agents and the property of partial agonist 
activity (Chapter 1.2.5).
A brief historical review (Chapter 1.3.1) on the discovery 
and subsequent elucidation of the roles of arginine 
vasopressin, is followed by a detailed review of the 
anatomy and physiology of its release in man, together 
with a discussion of the physiological roles and 
difficulties in investigation of these roles (Chapter 
1.3.2 - 1.3.3.).
I then review the current literature on arginine 
vasopressin in diabetes mellitus (in the absence of 
autonomic neuropathy) with reference to both osmotic and 
non-osmotic release of the peptide (Chapter 1.3.4). In 
order to provide a background to the studies in chapters 4 
- 6, the control of vasopressin release and the effects of 
exogenous vasopressin in the presence of disordered 
autonomic control of the circulation is considered, with
17
special reference to relevant animal studies, the human 
literature on subjects with pharmacological denervation, 
progressive autonomic failure, tetraplegics, cardiac 
transplant patients, and finally, diabetics with 
cardiovascular reflex test evidence of autonomic 
neuropathy (Chapter 1.3.5).
Chapter 2 details the methods and materials used in the 
studies presented in this thesis. Because different 
subjects were used in each study, their details are given 
in the individual results chapters.
In chapter 3, observations are presented from a randomised 
double-blind controlled study on eight diabetics with 
autonomic neuropathy in which cardioselective and non- 
cardioselective beta-adrenoceptor blocking agents both 
with and without partial agonist activity (PAA) (atenolol, 
epanolol and pindolol) were given in order to determine 
changes in heart rate (a Beta^ effect) and changes in 
physiological tremor (a Beta2 effect).
Relative changes in heart rate were observed which reflect 
the amount of partial agonism in these drugs. Pindolol, 
the drug with most partial agonism, raised heart rate 
compared with placebo at night time. Epanolol, with 
moderate PAA, had little effect on heart rate at night and 
atenolol/ with no PAA, lowered heart rate compared with
18
placebo throughout the 24 hour period.
Changes in physiological tremor were seen which reflected 
the cardioselectivity of the drugs used, in that that four 
hours post dose, pindolol, the non-selective drug with 
PAA, increased tremor compared with placebo, epanolol and 
atenolol, none of which affected tremor values.
A significant rise in plasma glucose was seen after 
pindolol only, which may demonstrate a heightened 
sensitivity of Beta2 -adrenoceptors in diabetics with 
autonomic neuropathy.
These results are compared and contrasted with those 
previously demonstrated in other forms of denervation, and 
suggest that denervation in autonomic neuropathy is not as 
complete as in either animal models or progressive 
autonomic failure.
In chapter 4, data from a study is presented in which 5 
normal controls, 5 diabetics without (DAN -ve) and 6 with 
(DAN +ve) cardiovascular reflex test evidence of autonomic 
neuropathy were studied by 5% saline infusion, to test 
whether, osmotic stimulation of AVP is disordered in 
diabetics with autonomic neuropathy. 5% saline infusion 
produced appropriate rises in plasma osmolality and AVP 
levels which did not differ between the three groups,
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confirming that osmotic release of AVP is normal in 
diabetic autonomic neuropathy. The blood pressure 
responses to this stimulus were similar, although one DAN 
+ve subject displayed a marked pressor response. The 
reasons for this are discussed with reference to other 
studies on PAF and tetraplegic subjects.
Chapter 5 looks at the cardiovascular and AVP responses to 
45° head-up tilt over 120 minutes in three groups; 6 
normal, 6 DAN -ve and 7 DAN +ve subjects. No differences 
in AVP responses were observed between the three groups, 
despite a major hypotensive stimulus in the group with 
autonomic neuropathy. This confirms that an afferent 
defect exists in the neural pathways which control AVP 
release in diabetic autonomic neuropathy. Such a pattern 
is also seen in patients with PAF, but contrasts with the 
response in subjects with selective efferent sympathetic 
loss secondary to spinal cord transection.
Plasma renin release to the same stimulus was found to be 
normal in DAN +ve subjects, in contrast to earlier work. 
It seems likely that deterioration in renal function 
causes low renin responses in diabetic autonomic 
neuropathy.
Chapter 6 studies the cardiovascular responses to an 
incremental infusion of AVP in physiological doses in 6
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normal, 8 DAN -ve and 8 DAN +ve subjects. No pressor 
responses were seen in the normal subjects, but marked 
increases in blood pressure were observed in most of the 
DAN +ve group and in two of the DAN -ve group. The 
responses tended to wane at the maximum AVP infusion rate.
As heart rate fell slightly in 611 three groups, the 
pressor response to AVP is unlikely to be secondary to the 
loss of baroreflex activation. More probably it
represents an increased sensitivity of the peripheral 
vasculature to vasopressin associated with autonomic nerve 
damage.
Chapter 7 presents a general discussion of these results 
in relation to other work on autonomic failure, both in 
diabetics and in other forms of denervation. The 
findings indicate that in these diabetics the concept of 
complete cardiac denervation is an untenable idea, and 
that the importance of neuropeptidergic and hormonal 
influences in maintaining homeostasis is not yet fully 
elucidated.
21
INTRODUCTION
The concept of the autonomic nervous system was first 
mooted in 1898 by Langley, to encompass the unconscious 
function of the "sympathetic" nervous system, the cranial 
and sacral nerves and the local gut innervation. Since 
then the apparent simplicity of this system has been 
confounded by subdivision into parasympathetic, adrenergic 
and cholinergic systems (Webber, 1978), the inclusion of 
endocrine influences and more latterly, the recognition 
that neuropeptide transmitters and opioids may have 
profound importance in its function (Reid & Rubin, 1987).
The integrity of the autonomic nervous system is essential 
to the maintenance of normal cardiovascular regulation in 
man. For instance, the ability to stand up is largely 
taken for granted, but underlying this simple manoeuvre is 
a complex interplay between several cardiovascular 
reflexes, which compensates for pooling of blood in the 
extremities by peripheral vasoconstriction and tachycardia 
to maintain the constant perfusion of blood to vital 
organs. Disruption of normal autonomic function may 
involve several of these sophisticated control mechanisms, 
leading to large postural changes in blood pressure and 
consequent cerebral hypoperfusion, hypoxia and syncope.
Examination of the effects of autonomic dysfunction on
22
single control systems in the body can be fraught with 
difficulty in interpretation. It is important to bear in 
mind that no function of the autonomic nervous system 
operates in total isolation from another, that a 
particular function may alter according to the stimulus 
effected on it, and that its purpose may change secondary 
to a pathological process. In an elegant model of
central nervous system regulation of cardiovascular 
function, such a concept was expressed as "dynamic 
spheres of influence" (Wurster, 1984) in which as an 
example, the separate neuronal circuits controlling sweat 
glands, vasopressin secretion and control of the heart 
were considered. What is perceived as a thermoregulatory 
control function to a temperature regulation physiologist 
may be considered as a water and electrolyte control 
mechanism to a renal physiologist, in other words each 
"separate" function overlaps with others and is dependent 
on the integrity of others to maintain homeostasis (figure 
!)•
The overview this concept provides is useful to bear in 
mind in this thesis. Although separate autonomic control 
systems will be considered in isolation, they are only 
isolated from each other in the context of the individual 
experiments, and that when autonomic control is 
disordered, the function and importance of the individual 
systems may take on a different emphasis.
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It is recogised that autonomic nervous system damage may 
occur in a variety of systemic disorders such as tabes 
dorsalis, polyneuropathies, amyloidosis, porphyria, 
chronic renal failure and chronic alcoholism (Johnson & 
Spalding, 1974; Bannister, 1983). Primary disorders may 
also occur, such as familial dysautonomia or the Riley-Day 
syndrome (Riley et al, 1949; Brunt & McKusick, 1970), and 
idiopathic orthostatic hypotension or the Shy-Drager 
syndrome (Bradbury & Eggleston, 1925; Bannister, 1983; Shy 
& Drager, 1960). The most commonly occurring form of 
autonomic neuropathy encountered in medical practice, 
however, is that which occurs in diabetes mellitus. 
Evidence for autonomic dysfunction is found in between 17- 
40% of all diabetics (Ewing, 1984). Abnormal autonomic 
function combined with symptoms carries a significant 
morbidity and mortality (Ewing & Clarke, 1986a).
It is against the background of a commonly occurring 
complication of a common disease that this thesis is set. 
By studying separate aspects of autonomic, neuroendocrine 
and hormonal control in diabetic autonomic neuropathy, I 
hope to demonstrate that the influence each factor is 
thought to exert in intact man changes in the presence of 
the pathological state; that it is the disruption of the 
autonomic nervous system, rather than the diabetic state, 
which is responsible for the change; and that by studying
24
diabetics with autonomic neuropathy, paradoxically we may 
further the understanding of normal autonomic control 
mechanisms in man.
25
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Dynamic spheres of influence
(A) Spheres of influence. Areas of the central nervous 
system involved in control of particular systems/ e.g. 
sweat glands, antidiuretic hormone release (ADH), and the 
heart, as schematically represented by areas containing 
neurones, a, b, and c, respectively.
(B) Overlapping spheres of influence. Control of 
different functions may involve neuronal circuits may 
overlap sweat gland and antidiuretic hormone control areas 
of spheres of influence.
(C) Dynamic spheres. The effective overlap of control 
systems may vary from one time to another and from one 
physiological state to another depending on the intensity 
of the regulatory drive or stimulus. The CNS is 
represented by the structures within the-dashed boxes.
(Adapted from Wurster, 1984 with permission)
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CHAPTER 1
CHAPTER 1.1 DIABETIC AUTONOMIC NEUROPATHY
1.1.1 Historical Aspects
Descriptions of clinical features which would now be 
recognised as being typical of diabetic autonomic 
neuropathy have appeared in the literature from the raid 
nineteenth century onwards. De Calvi, in 1864, is 
generally credited (in: Rundles, 1945) with the
recognition that neurological features (sciatic pain, 
peripheral anaesthesia and neurogenic bladder disturbance) 
may be a consequence, rather than the causation, of 
diabetes mellitus, as was previously thought.
Further case histories followed; Pavy (1885) described 
painful neuropathic symptoms with abnormalities of 
sweating, Buzzard (1890) and Pryce (1893) described 
vasomotor foot problems, and Pitres (1902) outlined 
absence of pupillary reflexes and loss of testicular 
sensation in diabetics.
At this time, the neurological features associated with 
diabetes were most closely related to those occurring in 
chronic alcoholism and tertiary syphilis - thus "diabetic 
pseudotabes" was frequently referred to. The diagnosis
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of ‘'so-called" diabetic neuropathy was often in doubt 
because of the reluctance of clinicians to attribute the 
neuropathic changes to diabetes, rather than "senile" 
changes or arteriosclerotic disease which was commonly co­
existent. Far from seeing these complications disappear 
after the introduction of insulin in 1922, more and more 
sufferers presented with diverse complaints such as 
gastric -fullness, postural hypotension, nocturnal or 
episodic diarrhoea, and sweating abnormalities. It was 
not until the appearance of two major reviews, by Jordan 
in 1936 and in particular, Rundles in 1945 that the 
clinical features of autonomic dysfunction in diabetes 
mellitus were fully recognised. Further descriptive
clinical reviews followed, such as those of Keen in 1959 
and Jadzinsky, Faerman & Fox in 1973, but in 1960 
Sharpey-Schafer and Taylor introduced the concept of 
applying simple cardiovascular reflex testing to 
demonstrate abnormalities in diabetes, using the Valsalva 
manoeuvre.
The use of, and subsequent expansion of these tests in 
1973 by Wheeler & Watkins in London and Ewing and others 
in Edinburgh has allowed the systematic study of large 
numbers of diabetics, and a classification of progressive 
damage to the autonomic nervous system has evolved. 
Inherent in the interpretation of these tests is the 
maxim that when cardiovascular reflexes are abnormal,
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other systems served by the autonomic nervous system are 
affected by neuropathic damage. This has been well
validated in clinical studies (1.1.3).
With the development of these tests, over the last fifteen 
years there has been an explosion in interest in diabetic 
autonomic neuropathy. Autonomic neuropathy is now 
recognised as a relatively common complication of 
diabetes. The shift in emphasis from a symptom-based 
classification of diabetic autonomic neuropathy, which 
will only pick up late (and by implication, severe) 
autonomic damage, to a definition based on objective and 
measurable criteria has been crucial to the in-depth study 
of the natural history and pathophysiology of this 
disorder.
1.1.2 Clinical features of diabetic autonomic neuropathy
In keeping with other systemic disorders which cause 
neuropathies, autonomic neuropathy secondary to diabetes 
may cause many clinical syndromes by its widespread 
nature. In order to put its clinical effects into
perspective, I will briefly outline the major clinical 
features found in this condition.
Cardiovascular
The most obvious feature of failure of cardiovascular 
autoregulation is of postural hypotension, first clearly
28
defined in diabetic autonomic neuropathy by Rundles 
(1945). Symptoms include lightheadedness, postural 
weakness, visual impairment or syncope, and these features 
may be worsened by insulin (Page & Watkins, 1976) owing to 
its effect in slightly reducing plasma volume (Gundersen & 
Christensen, 1977).
A resting tachycardia of between 90-100 beats per minute 
may be observed (Rundles, 1945; Keen, 1959; Wheeler & 
Watkins, 1973), but is probably not a specific marker for 
autonomic neuropathy, as diabetics as a group have faster 
heart rates than controls (Ewing, Neilson & Travis, 1984), 
whatever their "stage" of autonomic damage.
Painless or "silent" myocardial infarction is more 
prevalent in diabetics (Bradley & Schonfield, 1962) and 
this has been attributed to autonomic neuropathy, despite 
the fact that patients with known autonomic neuropathy may 
have typical pain of myocardial infarction (Campbell, 
Ewing & Clarke, 1978). Sudden death is also more common 
(Page & Watkins, 1978) but the mechanism of this is still 
unknown.
Gastrointestinal
Delayed gastric emptying (Rundles, 1945), or gastroparesis 
diabeticorum (Kassander, 1958) is usually asymptomatic, 
but may lead to loss of diabetic control with
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hyp°glycaemia (Campbell & Conway, 1960), weight loss 
(Wooten & Meriweather, 1961) or episodes of nausea and 
vomiting (Howland & Drinkard, 1963).
"Diabetic diarrhoea" is a relapsing and remitting 
condition, characterised by episodes of frequent watery 
stools, often nocturnal, with faecal incontinence (Bargen, 
Bollman & Kepler, 1936).
Colonic atony has also been described (Rundles, 1945), but 
may be secondary to other factors such as dehydration or 
immobility.
Genitourinary
De Calvi (1864), Jordan (1936) and Rundles (1945) all 
described bladder abnormalities. Nocturia out of
proportion to glycosuria was described by Rundles (1945) 
and "rediscovered" recently (Bell et al, 1987).
Impotence is often quoted as a feature of diabetic 
autonomic neuropathy, but may occur in diabetics for other 
reasons (Ewing, Campbell & Clarke, 1980).
Vasomotor/sudomotor
Both anhydrosis and vasomotor changes have been reviewed 
in diabetic autonomic neuropathy (Rundles, 1945; Martin, 
1953) aside from the original descriptions of Pavy and
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others (see 1.1.1). Compensatory upper body
hyperhydrosis may occur (Goodman, 1966), and gustatory 
sweating may also be troublesome (Watkins, 1973).
Pupillary changes
Pupillary abnormalities, such as small irregular pupils, 
absent light reflex or diminished hippus, have long been 
described (Pitres, 1902; Jordan, 1936; Rundles, 1945; 
Smith et al, 1978) and more recently have formed the basis 
for a simple test of autonomic function (Martyn & Ewing, 
1986).
Autonomic neuropathy may also be a cause of unawareness of 
hypoglycaemia in insulin dependent diabetics (Ewing & 
Clarke, 1986a).
Even in such a brief review of clinical features, it is 
apparent that autonomic nerve damage in diabetes can cause 
significant problems. For a more complete picture the 
reader is referred to Rundles (1945), Clarke, Ewing & 
Campbell (1979), Ewing & Clarke (1986a) and Ewing & Clarke 
(1986b).
1.1.3 Natural history of diabetic autonomic neuropathy
Abnormalities of cardiovascular autonomic function tests 
occur in between 17-40% of consecutive or randomly 
selected diabetic adults (Ewing & Clarke, 1982; Ewing,
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1984). Thirty one per cent of a teenage cohort (Young, 
Ewing & Clarke, 1983) and 15% of younger diabetic children 
(Mitchell, Wealthall & Elliot, 1983) also had abnormal 
cardiovascular reflexes, though no symptoms of autonomic 
neuropathy were observed in these groups. Symptomatic 
autonomic neuropathy is rare in young diabetics, although 
it has been reported (Lloyd-Mostyn & Watkins, 1976; Blum 
et al, 1980). Predictably, symptoms of diabetic 
autonomic neuropathy increase in prevalence with longer 
durations of diabetes (Canal et al, 1978; Masaoka et al,
1985).
Cardiovascular reflex autonomic function tests have been 
found to show a gradation of damage in autonomic 
neuropathy (Bennett, 1983). The heart rate tests, which 
are thought predominantly to reflect vagal damage, are 
more commonly abnormal than blood pressure tests (thought 
to reflect predominantly sympathetic abnormalities) when 
groups of diabetics are studied. In interpreting the 
results of these tests, their sensitivities have to be 
borne in mind. The heart rate tests are much more 
sensitive than blood pressure tests and are more likely to 
display abnormalities. Despite this, cardiac vagal 
nerves appear to be affected before sympathetic nerves 
(Bennett, 1983), possibly because they are longer and more 
susceptible to damage (Ewing, Campbell & Clarke, 1981).
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The tests also show deterioration with time; in a large 
group of diabetics whose tests were repeated three months 
or more apart, 71% had unchanged tests and 26% had 
deteriorated (Ewing et al, 1985). This phenomenon has 
been repeatedly observed.
Abnormal cardiovascular reflexes and symptoms of autonomic 
damage have been found to correlate well (Ewing et al, 
1980; Mackay et al, 1980). In these studies, symptoms of 
autonomic neuropathy (other than impotence) were strongly 
related to cardiovascular reflex test abnormalities. 
When taken together, the presence of abnormal tests and 
symptoms has great prognostic significance. A mortality 
rate of 50% in 2.5 years was found in one study (Ewing et 
al, 1980) and patients with most test abnormalities were
found to have the highest fatality rate (Clarke & Ewing,
1982). Higher mortality rates in diabetic autonomic
neuropathy have been confirmed in other studies, most 
notably Watkins & Mackay (1980).
1.2 Neural control of the heart
This section of my dissertation will concern itself with 
some of the background aspects of neural control of the 
heart which are essential to the studies presented later 
in the thesis. Cardiovascular control mechanisms are, of 
course, very complex; the relationship between neurally 
mediated changes in heart rate, stroke volume, blood
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pressure and respiration cannot in reality be separated 
from changes in neuroendocrine function either within the 
central nervous system (for example, catecholamines, 
serotonin, GABA and various neuropeptides) or in the 
periphery (where adrenal hormones, renin or thyroid 
hormone may, for example, exert powerful cardiovascular 
effects). The "spheres of influence" (see introduction) 
they exert upon each other are irrevocably linked. In 
order, however, to review those parts of cardiovascular 
control relevant to this thesis, I will consider such 
systems in isolation.
1.2.1 Anatomical considerations
Sympathetic efferent fibres originate in the upper 
thoracic segment of the spinal cord. The cell bodies of 
these preganglionic neurones are largely concentrated in 
the intermediolateral cell column, and leave the spinal 
cord via the ventral roots. They then run for a short 
distance with the spinal nerves before separating to form 
the white rami communicantes. After running to the
sympathetic ganglia, unmyelinated fibres then leave, 
mainly along the adventitia of the great vessels and the 
atrial walls to reach most parts of the heart. 
Noradrenaline released from the sympathetic nerves in 
addition to catecholamines diffusing from the bloodstream 
interact with adrenoreceptors on heart cells which leads 
to alterations in their physiological performance.
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Parasympathetic fibres arise in the medulla from the vagal 
nuclei and make up a part of the vagus nerve. Fibres 
from the left and right vagus nerves enter the heart at 
atrial level, synapse in cardiac cholinergic ganglia and 
exert their effects through release of acetylcholine (ACh) 
from postganglionic fibres primarily in the atria, but 
also in the ventricles.
The major inputs to the brain which facilitate 
cardiovascular regulation include afferent fibres from 
arterial baroreceptors and chemoreceptors, and from 
cardiopulmonary receptors and lung stretch receptors, 
which run via and IX and Xth cranial nerves to the 
medulla, terminating in the region of the nucleus of the 
tractus solitarius (NTS), the primary relay for 
cardiovascular afferents in the brainstem. Spinal 
somatic and visceral afferent nerves, including 
sympathetic afferents from the heart and vessels are 
involved, in addition to receptors in joints and skeletal 
muscles. The sense organs, thermoreceptors and receptors 
innervated by the trigeminal nerve also function in 
cardiovascular control.
1.2.2 Physiological effects of afferent inputs
The walls of certain blood vessels (mainly the aortic arch 
and carotid bifurcation) contain receptors, termed
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baroreceptors, which are activated by mechanical 
deformation secondary to stretching of the vessel wall. 
The nerve endings lie mainly in the adventitia of the 
arterial wall and form a dense arborization.
Stimulation of the arterial baroreceptors results in a 
bradycardia and hypotension, this being mediated by 
enhanced vagal discharge together with decreased 
sympathetic output (Kircheim, 1976).
The main effects following stimulation of arterial 
chemoreceptors (mainly situated in the aortic and carotid 
bodies) include a rise in parasympathetic and a fall in 
sympathetic activity to the heart, producing bradycardia, 
while vasoconstriction in the major vascular beds and 
increased secretion of adrenal catacholamines are brought 
about by an increased efferent sympathetic discharge, 
increasing total peripheral resistance to such a degree 
that arterial pressure increases. These effects are only 
seen when respiration is kept constant by artificial 
means, for chemoreceptor activation produces a dramatic 
increase in both rate and depth of respiration such that 
vasodilatation occurs, producing a tachycardia and 
increase in cardiac output. Similar effects are seen 
after central chemoreceptor stimulation, secondary to 
brainstem pH changes. Chemoreceptor mechanisms are thus 
"emergency" regulatory systems, unlike baroreceptor
36
functions, which have an on-going regulatory role.
Cardiac receptors have been found in the coronary vessels 
and throughout the heart, and mediate many different 
reflexes through both sympathetic and vagal pathways 
(Brown, 1979).
Lung stretch receptors are activated primarily by 
pulmonary inflation, and their cardiovascular effects 
include reflex vasodilatation in the skin, muscle and 
splanchnic beds due to a decrease in sympathetic efferent 
activity.
Spinal inputs from various receptor sources, such as from 
muscles and joints, skin pain receptors and various 
receptors in the vasculature may elicit some 
cardiovascular effects. Isometric muscle contraction, 
for example, leads to a dramatic increase in blood 
pressure and heart rate due to an augmented sympathetic 
outflow mediated by this means.
1.2.3 Sympathetic/parasympathetic interactions in the 
heart
In general terms, neural control of cardiac function can 
be divided into sympathetic and parasympathetic, or 
alternatively, adrenergic and cholinergic effects. Both 
atrial and ventricular contractility are greatly enhanced
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by sympathetic stimulation, resulting in increased stroke 
work at a given filling pressure, and greater systolic 
emptying (increased ejection fraction) which decreases 
end-systolic volume. Increased parasympathetic tone 
decreases atrial contractility, but has only a small 
negative inotropic effect on the ventricles (Higgins, 
Vatner & Braunwald, 1973).
Independent of innervation, the heart increases its output 
as venous return is increased (Frank-Starling effect). 
An increase in heart rate also augments the contractile 
force of the heart (Bowditch effect). An increase in 
aortic pressure (increased afterload) will also cause an 
increase in contractile force (Anrep effect).
Control of heart rate may be viewed in simplistic terms as 
having a quick-onset, vagus mediated “brake" and a 
sympathetic "accelerator", acting over a longer period of 
time. The reality is much more complex: there is a
constant and varying balance between cardiac vagal and 
sympathetic influences that determines the heart rate at 
any given time or circumstance. It is clear that this 
process is not a simple algebraic summation of adrenergic 
and cholinergic effects; the vagus exerts a 
disproportionate inhibition of the cardiostimulatory 
effects of sympathetic stimulation ("accentuated 
antagonism"), probably by both reducing the amount of
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noradrenaline released by the sympathetic nerve ends, and 
by a direct cholinergic attenuation of the magnitude of 
the intracellular response in the heart (Levy, 1971; 
Higgins, Vatner & Braunwald, 1973; Levy & Martin, 1984).
Conversely vagal stimuli may produce a paradoxical 
sympathetic response and vice-versa. This phenomenon is 
known as."reciprocal excitation", and may occur secondary 
to (a) the presence of sympathetic fibres in a 
predominantly parasympathetic nerve trunk, (b) cholinergic 
stimulation of cardiac activity evoked by noradrenergic 
mechanisms, and (c) cholinergic stimulation of the heart 
mediated by adrenergic mechanisms (Levy & Martin, 1984). 
Despite the complexity of these neural interactions, the 
working model of vagal "brake" and sympathetic 
"accelerator" is still a useful concept, paticularly when 
denervation is considered (see 1.2.4).
1.2.4 The denervated heart
The heart may be deprived of neural influence in three 
ways; by surgical section of sympathetic and 
parasympathetic nerves leading to the heart, by 
pharmacological depletion or blockade of transmitter 
substances and receptors, or by the pathological processes 
which lead to autonomic nerve damage. Even after 
"denervation" is accomplished by these means, complete 
denervation may not occur, as neuropeptidergic or
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endocrine influences may maintain other, intrinsic cardiac 
reflexes. In broad terms these different processes lead 
to a common end-effect, and may be regarded as analogous 
to one another, but differences exist which will be 
considered in view of the study presented in chapter 3.
Surgical denervation in man may be most completely 
achieved .by removal and reimplantation of the heart, as in 
cardiac transplantation. In excising the heart both 
afferent and efferent nerves are severed. Efferent 
fibres of the vagus, which are preganglionic, are 
sectioned as they enter the atria, abolishing cholinergic 
effects on the heart, but leaving cardiac cholinergic 
neurones and postganglionic fibres intact. Efferent
sympathetic nerves are postganglionic, and dividing them 
inactivates cardiac adrenergic neurones, leading to 
depletion of noradrenaline. The adrenoreceptors remain
intact, but may develop supersensitivity to exogenous 
catecholamines, probably by changes in neuronal uptake 
(Kaye, 1984).
The effect of surgical denervation on heart rate in man is 
to produce a moderate tachycardia which does not respond 
to stimuli that would normally reflex the influenced heart 
rate (Shaver et al, 1969). Beat-to-beat variation, or 
sinus arrhythmia, is under vagal control, and is also lost 
following transplantation. After transplantation, the
40
atrial remnant of the recipient is left intact, but is 
separated from the donor heart by a suture line. In this 
circumstance there are two independent atrial rates, the 
recipient atrium beating at a slower rate than the 
transplanted one, as it is still subject to vagal 
influence, which is lacking in the transplanted donor 
heart. The recipient atrial remnant responds to neural 
control - for example, slowing of rate occurs when 
arterial pressure rises, but the donor heart remains 
uninfluenced (Kent & Cooper, 1974).
The transplanted heart increases its rate following 
exercise largely as a result of an increase in circulating 
catecholamines. This response may be blocked by beta- 
adrenoreceptor blocking drugs. Thus, although intrinsic 
mechanisms still remain to influence heart rate, 
denervation means that the heart is more reliant on 
extrinsic control to effect rate changes.
Pharmacological means may produce denervation. In 
animals, syringosopine will deplete catechols 
irreversibly. Fortunately, in human studies it is more 
usual to "denervate" subjects reversibly, by using 
intravenous atropine and propranolol. Such blockade
leads to a moderate tachycardia, which is not influenced 
by normal cardiovascular reflexes, as in the transplanted 
heart. The concept of "intrinsic heart rate" was
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developed by Jose & Collison in 1970 to describe a heart
denervated by drugs.
Much is now known about denervation secondary to autonomic 
neuropathy, particularly in the most common form, 
occurring in diabetics. They display moderate
tachycardia, loss of R-R variation and lack of response to 
tests of. cardiovascular reflexes. In many ways the 
situation resembles both surgical and pharmacological 
denervation. Kaldor et al (1977) compared the heart rate 
of diabetics with autonomic neuropathy with the intrinsic 
heart rate of both normal subjects and diabetics, without 
autonomic neuropathy and found them to be similar. Heart 
rate increases when autonomic damage first occurs, is 
shown to increase further as more reflex tests become 
abnormal, and finally drops slightly as all tests become 
abnormal (Ewing, Campbell & Clarke, 1981). This seems to 
mirror the changes seen in pharmacological blockade, where 
atropinisation causes a tachycardia, and propranolol leads 
to a small drop in heart rate thereafter (Leon, Shaver & 
Leonard, 1977).
Thus when 'neural' denervation occurs in man, intrinsic 
systems become more important in maintenance of heart 
rate, and extrinsic peptidergic or hormonal control may 
play an important part in altering cardiac function. 
Chapter 3 will discuss one such study in which heart rate
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control in denervated diabetics is influenced by drugs.
1.2.5 Beta-adrenoreceptors and partial agonist activity
Beta-adrenergic receptors are present in almost all 
mammalian tissues. Both betai and beta2 adrenergic 
receptors stimulate the membrane-bound enzyme adenylate 
cyclase, which leads to the intracellular accumulation of 
adenosine 3:5 cyclic phosphate (cyclic AMP), which acts as 
the "second messenger", and by phosphorylation of certain 
proteins influences the rate of calcium flux across cell 
membranes, thus altering the activity of the cells 
affected. The classification of beta-receptors into
betai and beta2 is based on pharmacological grounds 
(Lands, Luduena & Buzzo, 1967), but has been confirmed by 
direct radioligand binding studies (Lefkowitz, Caron & 
Stiles, 1984).
Pharmacological classification of receptor subtype (ie 
beta^ or beta2 ) depends on their responses to certain 
agonists: betai receptors are defined by the potency
series isoprenaline > adrenaline > noradrenaline > 
phenylephrine, whereas beta2 receptors show a more marked 
response to adrenaline, ie isoprenaline > adrenaline >> 
noradrenaline > phenylephrine. In other words, in 
vascular and bronchial smooth muscle, adrenaline is 
approximately tenfold more potent than noradrenaline in 
stimulating the (beta2 ) receptors, whereas in the heart
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and adipose tissue, adrenaline and noradrenaline are 
roughly equipotent at the (betai) receptors.
Agonist potency therefore became the method by which 
receptor subtype (betai or beta2 > was defined, but 
following the development of beta-adrenoreceptor blocking 
agents in the late 1950's and early 1960's, it became 
apparent, that the compounds synthesised had different 
blocking effects on infused agonists. Propranolol, a 
non-selective (betai anc* beta2 ) adrenoreceptor blocking 
agent displayed equal antagonism at both receptors, 
whereas practolol, a betai selective antagonist failed to 
block the effects of beta2 agonists to the same extent. 
The use of selective antagonists to define receptor 
populations can be criticised on the grounds that agonist 
potencies were originally used to define the receptors, 
but their use is well supported in the literature (Stiles, 
Caron & Lefkowitz, 1984).
The effects of the two receptors in physiological terms 
are quite different; betai stimulation produces 
stimulation of rate and force of contraction in the heart, 
activation of lipolysis in the liver and stimulation of 
amylase secretion by the salivary glands all by 
postsynaptic effects, whereas beta2 effects include smooth 
muscle relaxation in bronchi, blood vessels, and 
genitourinary and gastrointestinal tracts. In the liver
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they facilitate noradrenaline release and increase 
glycogenolysis and gluconeogenesis. Glycogenolysis is 
increased in muscle cells. Pancreatic secretion of 
insulin and glucagon is facilitated, and beta2 receptors 
in the juxtaglomerular apparatus are responsible for renin 
release. Beta2 receptors are present both
presynaptically and postsynaptically, and are also found 
on lymphocytes and polymorphonuclear leucocytes.
Beta-adrenoreceptor blocking agents can therefore be 
classified as selective or non-selective according to 
their relative ability to antagonise betai adrenoreceptors 
in some tissues at lower doses than those required fo 
beta2 receptors in other tissues. "Cardioselective"
beta-adrenoreceptor antagonists inhibit cardiac betai 
adrenoreceptors but exert little effect on bronchial and 
peripheral vascular beta2 adrenoreceptors. The
"cardioselective" blockers are considered so because the 
heart contains predominantly betai receptors and very few 
beta2 receptors. "Selectivity" of these compounds is a 
relative term, however, for as dosage is increased, 
increasing effects on beta2 receptors are seen in vivo 
(Frishman, 1981).
Beta-adrenoreceptor antagonists are all analogues of the 
agonist isoprenaline. Although they bind to the receptor 
in much the same way as isoprenaline, their structural
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properties mean that stimulation of the receptors does not 
necessarily occur. When they combine with the receptor, 
they produce beta-adrenoreceptor blockade by preventing 
access of agonist molecules to the receptor. Such "pure" 
blockade occurs for example in the cases of propranolol 
(non-selective) and atenolol (betai selective). Other 
kinds of beta-adrenoreceptor antagonists, such as 
pindolol-, or practolol, respectively non-selective and 
selective, again combine with the receptor to prevent 
access of agonist molecules. However, these drugs, by 
nature of their structure, actually exert a weak agonist 
activity on the receptor, and produce stimulatory effects. 
This property was originally termed intrinsic 
sympathomimetic activity (ISA), but is now more commonly 
referred to as partial agonist activity (PAA), a more 
accurate terminology in pharmacological terms.
The clinical significance of drugs possessing partial 
agonism is not entirely clear, but since their development 
they have provided insights into beta-adrenoreceptor 
function. One such study will be presented in chapter 3.
1.3 Vasopressin (AVP = Arginine vasopressin)
The studies contained in chapters 4, 5 and 6 are concerned 
with the relationship between the posterior pituitary and 
the cardiovascular system in diabetics both with and
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without denervation produced by autonomic neuropathy. In 
order to place my work in the context of the (rapidly 
expanding) literature on vasopressin, I will review the 
current knowledge of this peptide hormone. Firstly, a 
brief historial introduction will set the scene for a 
review of the physiological release mechanisms involved in 
both salt and water, and blood pressure homeostasis in 
man. A consideration of the receptors involved in 
producing the end organ effects will follow. The effects 
of exogenous vasopressin and its analogues in normal 
subjects will be reviewed.
The diabetic state, although little studied until 
recently, may produce further changes in the release of 
vasopressin and its actions. I will therefore consider 
the literature on this separately.
Denervated states have been shown to influence both 
secretion of vasopressin and the peripheral actions of the 
hormone. By reviewing what is known about AVP in other 
forms of autonomic neuropathy and pharmacological 
manoeuvres which produce 'denervation', in addition to the 
present knowledge of vasopressin in diabetic autonomic 
neuropathy, I hope to show that the studies presented in 
chapters 4, 5 and 6 help to answer questions raised by the 
literature in its present form.
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1.3.1 Historical review
In 1895, Oliver and Schafer reported that pituitary 
extracts caused a pressor response when injected into 
anaesthetised animals. The discovery that the active
pressor agent was confined to the posterior pituitary was 
made three years later (Howell, 1898), when vagotomised 
dogs were shown to have a larger rise in blood pressure 
than intact animals. The name "vasopressin" arose
because pressor bioassay became the standardisation 
technique for the pharmacopoeia.
In parallel with the work on pressor responses, other 
extracts of "pituitrin" were being studied in the 
treatment of diabetes insipidus. Isolated kidney work 
performed by Starling and Verney (1924) established more 
fully the antidiuretic properties of this extract. The 
work of this group over the next twenty years elaborated 
the physiological role of antidiuretic hormone in water 
balance (Verney, 1947).
It was only in 1953 that Du Vigneaud and co-workers proved 
that the two peptides were one and the same. It was seen 
that vasopressin had both pressor and antidiuretic 
properties. The importance of vasopressin in
cardiovascular regulation was largely ignored, because it 
seemed that only large pharmacological doses of AVP 
produced haemodynamic effects. However, following the
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introduction of sophisticated radioimmunoassay for AVP 
(Robertson et al, 1973), which allowed the measurement of 
low, and therefore physiological levels of the peptide, 
its role in both salt and water homeostasis and 
cardiovascular control has been increasingly recognised.
1.3.2 Osmotic and non-osmotic release of vasopressin
The secretion of vasopressin from the hypothalamo- 
neurohypophyseal system, although a neural function, is 
very similar to endocrine secretion of hormones from 
glands elsewhere in the body. A nonapeptide is
manufactured by proteolytic cleavage of a high molecular 
weight precursor. This is then released directly into 
the blood stream. Much has been learned of the mechanism 
by which this occurs by analysis of genetic material which 
now allows study of the human gene from which vasopressin 
is derived (Majzoub, 1985). The anatomical and
physiological background to the release of AVP is worth 
considering prior to discussion of factors affecting its 
release.
The hypothalamus lies at the anterior end of the 
diencephalon. It embodies a group of nuclei that form 
the floor and ventrolateral walls of the triangular-shaped 
third ventricle, the anterior boundary of which is made up 
of a thin membrane called the lamina terminalis; the 
osmoreceptor cells are believed to be sited there in a
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structure known as the organum vasculosum of the lamina 
terminalis (OVLT). This structure, like the pituitary 
gland, lacks a blood-brain barrier and is thus suited to 
its putative purpose of sensing osmotic changes in the 
blood. The supraoptic nucleus (SON) and paraventricular 
nucleus (PVN) lie respectively just dorsal to the optic 
chiasm and in the suprachiasmatic portion of the 
hypothalamus. They contain the majority of the large 
neurosecretory cells, or magnocellular cells which 
manufacture vasopressin and oxytocin (OT), the closely 
related posterior pituitary nonapeptides. These 
magnocellular cells project to multiple areas of the CNS, 
but the cells concerned with secretion of AVP and OT 
project to the neurohypophysis or posterior pituitary.
The vasopressin prohormone is manufactured in the 
magnocellular cell body at hypothalamic level, packaged 
into membrane-bound granules and cleaved during axonal 
transport to the axonal bulbs of the neurohypophysis where 
the storage of the final hormone takes place. It is 
finally released by exocytosis into the systemic 
circulation (Sklar & Schrier, 1983).
The "final common pathway" of vasopressin secretion is 
therefore stimulation of the magnocellular neurones in the 
hypothalamus. The stimuli to release of vasopressin may 
be divided into two main kinds; osmotic and non-osmotic.
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Osmotic release
Verney (1947) first proposed that release of vasopressin 
took place in response to various osmotic stimuli, and not 
purely to changes in sodium concentration, by showing in 
conscious dogs, that both sodium-rich and non-sodium 
containing hypertonic solutes produced comparable 
vasopressin responses.
These and subsequent investigations used indirect or 
urinary measurements to assess vasopressin function. 
Once a sensitive radioimmunoassay was established 
(Robertson et al, 1973), it became apparent that a close 
relationship existed between plasma osmolality and plasma 
vasopressin in healthy individuals.
By infusing human subjects with hypertonic saline, a 
linear relationship is seen between plasma osmolality and 
plasma AVP concentrations. The slope of the regression 
line obtained represents the sensitivity of the system in 
responding to osmotic change. For every unit rise in 
plasma osmolality, plasma vasopressin rises by 0.63 pmol 
1”1, or to express this differently, a change in plasma 
osmolality of one per cent alters plasma vasopressin by 
1.8 pmol 1“1. Maximum water diuresis is achieved at 
plasma AVP levels of around 5 pmol 1“*« The
extraordinary sensitivity of this control system underlies
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much of sodium and water balance in man.
The other important variable defined by the regression co­
efficient is the threshold or 'set-point' of the osmostat, 
defined by the abscissal intercept. This defines the 
plasma osmolality above which plasma vasopressin starts to 
increase. Genetic or environmental factors may be 
important in determining the osmotic threshold for 
vasopressin release in man. Most studies from Western 
countries suggest that the threshold is around 280-289 
mOsm kg"1 (Baylis, 1987; Schrier, Berl & Anderson, 1979) 
whereas studies in occidental man have shown the threshold 
to be lower, at approximately 265 mOsm kg"1 (Shimamoto, 
Murase & Yamaji, 1976). There is also great individual 
variation in the osmotic threshold for AVP release, and 
the sensitivity, or slopes of the regression lines vary 
between subjects. Despite this wide range of individual 
variation, it is said that any specific individual 
demonstrates similar values when studied over a period of 
time (Robertson, Shelton & Athar, 1976), allowing the use 
of subjects as their own controls in serial studies.
From other work, reviewed by Baylis (1987), it is clear 
that infusions of different solutes are sensed in 
different ways. Hypertonic saline and mannitol produce 
equivalent release of AVP in subjects, but hypertonic urea 
provides a poor stimulus for release. The release of AVP
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by hypertonic glucose will be considered elsewhere in this 
thesis, but in normal man it fails to stimulate AVP 
secretion (Zerbe & Robertson, 1983).
It appears, therefore, that solutes such as glucose, which 
readily penetrate cell membranes, do not greatly affect 
AVP release, but those which cross membranes with 
difficulty, for example, sodium, will set up an osmotic 
gradient across the cell, causing intracellular water to 
flow into the extracellular compartment, leading to a 
decrease in cellular volume by intracellular dehydration. 
Thus it seems that the osmoreceptor acts by changing its 
cellular volume (Robertson et al, 1976; Zerbe & Robertson,
1983). This hypothesis is an attractive one, but it is 
difficult to prove. In theory, it should be possible to 
demonstrate a suppression of AVP release when cell 
swelling occurs, but as baseline levels of AVP are low, 
the detection limits of current assays limit work on these 
lines.
Osmoreceptor function varies with age: in one study
(Helderman et al, 1978), the release of AVP to osmotic 
stimulation was greater in an older group of subjects, 
with no differences in the osmotic thresholds between the 
groups. It appears that the sensitivity of osmotic 
control of vasopressin secretion improves with age, in 
contrast to most other physiological mechanisms in man.
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In addition to age, pregnancy and the menstrual cycle can 
affect osmoregulation in humans (Baylis, 1987).
Non-osmotic release
It seems, therefore, that there is a sensitive mechanism 
by which changes in osmotic pressure regulate vasopressin 
release, .but it also became apparent that its release 
could be produced by other means. Verney, in his 
Croonian lecture (1947), produced evidence of antidiuresis 
caused by the "emotional stress" of electrically 
stimulating the flanks of dogs during a water diuresis. 
This manoeuvre produced a small and transient 
antidiuresis, but was accompanied by a large increase in 
blood pressure. This antidiuresis was shown to be 
related to vasopressin (O'Connor & Verney, 1942).
More recent work has shown that catecholamines are 
implicated in this response. Schrier et al (1975) showed 
that both alpha-adrenergic (diuresis-producing) and B- 
adrenergic (anti-diuresis-producing) effects on renal 
water excretion are mediated mainly by alterations in the 
secretion of vasopressin, the mechanism acting through the 
baroreceptor pathways. Both the low and high pressure 
baroreceptors are implicated in this response (Schrier, 
Berl & Anderson, 1979). Changes in blood volume and 
blood pressure are relayed from cardiovascular receptors
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in the carotid sinus and thorax, possibly the ventricles 
(Wang et al, 1988; Quail, Woods & Korner, 1987) via the 
glossopharyngeal and vagal cranial nerves to the nucleus 
tractus solitarius (NTS) and thence the paraventricular 
and supraoptic nuclei of the hypothalamus via 
predominantly catecholaminergic pathways.
Hypotension, with or without hypovolaemia, has been shown 
to be a potent stimulus to vasopressin release, 
hypotension acting on the high pressure (carotid sinus) 
baroreceptors, and hypovolaemia on the low pressure (ieft 
heart) receptors. Orthostasis, achieved by head-up tilt, 
has also been shown to stimulate vasopressin secretion 
(Davies et al, 1976). By infusing ganglion blocking 
drugs to lower blood pressure in a controlled manner, 
large quantities of vasopressin are released. In
contrast to the linear relationship between osmotic 
stimulation and vasopressin release, the relationship 
between the percentage fall in mean arterial blood 
pressure during infusion and plasma vasopressin level is 
exponential. Baylis (1987) has claimed that falls in 
blood pressure of only 5% may produce significant changes 
in plasma vasopressin concentration (approximately 1 pmol 
1”*) within the range that influences urinary 
concentration. The sensitivity of baroregulatory release 
of AVP is, however, considerably less than that of 
osmoregulatory release, although it is argued that small
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blood pressure changes may influence short term control of 
renal water excretion. There is evidence that, unlike 
osmotic regulation of AVP, baroreflex-mediated release 
becomes less sensitive with increasing age (Rowe et al, 
1982).
Although two discrete pathways mediate AVP release, there 
is a complex and little understood interplay between 
osmotic and non-osmotic influences. Despite degrees of 
hypotension and/or hypovolaemia, which increase plasma AVP 
levels, osmoregulation of vasopressin remains intact, 
although a lower set point for vasopressin release is 
produced (Robertson & Athar, 1976; Baylis, 1987; Schrier 
et al, 1979). In addition, osmotic release of AVP may be 
suppressed by baroreceptor influences (Goldsmith, 1988).
Another potent stimulus to AVP release in man is nausea or 
emesis. Rowe et al (1979) showed that apomorphine-
induced nausea or vomiting caused rises in plasma 
vasopressin concentrations independent of changes in blood 
pressure, blood volume, or intrathoracic pressure.
Drinking in humans may also play a part in non-osmotic 
suppression of vasopressin release. Recent work has 
shown that osmotic stimulation of thirst and AVP displays 
similar characteristics, and that transient inhibition of 
both thirst and AVP release may take place through
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swallowing reflexes, independent of the prevailing plasma 
osmolality. This suggests that non-osmotic neuronal 
pathways from the oropharynx mediate changes in thirst 
perception, probably in a protective role to prevent 
sudden overhydration of the brain and its consequences 
(Thompson et al, 1987/ Seckl, Williams & Lightman, 1986).
Hypoglyc^emia is known to raise vasopressin levels in man, 
but the precise mechanism is unknown as yet. Whether it 
occurs as a direct effect of neuroglycopenia on the 
hypothalamus (Thompson et al, 1981; Fisher, Baylis & 
Frier, 1987), or is secondary to other considerations 
(Thompson et al, 1989) is not clear. It appears that 
there is an exaggerated response of AVP to hypoglycaemia 
in type I diabetics, and it is possible that through the 
action of AVP on hepatic glycogen phosphorylase, this may 
be a heightened counter-regulatory response to impaired 
glucose recovery in diabetes (Fisher et al, 1989), as AVP 
has been shown to raise blood glucose in normals (Spruce 
et al, 1985).
It is apparent, therefore, that apart from osmotic 
changes, many non-osmotic factors influence the release of 
AVP from the posterior pituitary. Although they are
directed primarily through two separate pathways to act 
upon the hypothalamus, it is clear that they may act 
together to release AVP into the circulation. There is
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obviously a complex mechanism within the autonomic nervous 
system by which changes in the balance of sympathetic and 
parasympathetic discharge regulate non-osmotic release of 
AVP. Thus, parasympathetic afferents which lead to the 
hypothalamus are influenced by changes in “tone" which 
occur during stress situations such as pain, rapid 
decreases in cardiac output, acute hypoxia, psychiatric 
disturbances and acute adrenal insufficiency (Schrier et 
al, 1979).
Considerable work will be required to elucidate the 
relationships between osmotic and non-osmotic release of 
arginine vasopressin in man. Much of it is now under 
way.
1.3.3 The roles of vasopressin
The discovery that different structural analogues of 
arginine vasopressin could produce widely varying actions 
on different tissues led to work which identified specific 
peripheral tissue receptors, which have since been 
characterised as Vi and V2 receptors. In addition, there 
is work that suggests the existence of as yet 
uncharacterised receptors within the central nervous 
system (Manning & Sawyer, 1985).
Vi receptors have been found in vascular smooth muscle 
(Schiffrin & Genest, 1983), in liver cells (Cantau et al,
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1980), and in various parts of the kidney (Dousa, 1985). 
V2 receptors are located in the renal tubule (Guillon et 
al, 1982). The stimulation of Vi receptors produces 
vasoconstriction, by stimulating phosphatidylinositol 
turnover (Creba et al, 1983), whereas V 2 receptor 
stimulation brings about reabsorption of free water in the 
renal tubule - the antidiuretic effect.
The antidiuretic response involves activation of membrane- 
bound adenylate cyclase and the generation of cyclic AMP 
as a second messenger (Roy, Barth & Jard, 1975), whereas 
the contractile response of vascular smooth muscle and the 
glycogenolytic response of hepatocytes act independently 
of cyclase activation via generation of intracellular 
calcium. This is analogous to the designation of 
histamine receptors as Hi and H2 . Hi receptors do not 
appear to mediate the activation of adenylate cyclase, but 
H2 receptors do.
Investigation of the role of AVP is also complicated by 
the fact that simply measuring plasma levels of the 
hormone may not reflect its activity in vivo. It is now 
clear that AVP containing neurones have a variety of 
central projections that impinge on important 
cardiovascular regulatory areas (Swanson & Sawchenko, 
1980) and thus AVP may influence cardiovascular functions 
in circumstances under which plasma AVP levels are
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unaffected. To further complicate matters, the discovery 
of an AVP-like peptide localised to peripheral sympathetic 
nerve cell bodies, intraganglionic axons and terminal 
fibres in various viscera (Hanley et al, 1984) may imply 
that peptidergic nerves store a biologically active 
substance which behaves like AVP, yet is undetectable by 
normal assays. In addition to this, it may be possible 
that under some circumstances, AVP neurones might 
establish new neuronal pathways which influence 
cardiovascular regulation (Silverman & Zimmerman, 1982).
The effects of vasopressin on the kidney are relatively 
well known, but it is in the field of cardiovascular 
regulation that its role has become recognised in the last 
fifteen years. Once again, however, it is clear that 
there are pitfalls in interpretation of experimental data 
involving both animals and man.
Bennett & Gardiner (1986) in a criticial review of the 
literature on the effects of exogenous AVP on baroreflex 
mechanisms, pointed out the wide inter-species variation 
in the results obtained, and in their interpretation by 
investigators. Most of the work reviewed involved 
modifications of some kind to the autonomic nervous 
system, the renin angiotensin system or to AVP levels 
themselves. In a separate review, the , same authors
(1985) remind us that cardiovascular regulation involves
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subtle interactions between these three control systems, 
and that interference with any of these may merely prompt 
the remaining mechanisms to adjust to the interference, 
perhaps producing spurious results.
It is with this background that its effects are reviewed. 
Experimental work has shown that AVP is a powerful 
vasoconstrictor (Altura & Altura, 1984), but that it 
exerts differential effects and different vascular beds 
(Monos, Cox & Peterson, 1978; Liard et al, 1982). 
Despite this, studies in both animals and man show wide 
inter-species variation in AVP concentrations required to 
produce a pressor response (Bennett & Gardiner, 1986). 
Normal human subjects seem to be particularly insensitive 
to its pressor effects (Williams et al, 1986; Aylward et 
al, 1986; Simpson et al, 1986; Mohring et al, 1980; 
Padfield et al, 1976). It is clear, therefore, that 
mechanisms which buffer the blood pressure changes in 
these subjects come into play. Animal work suggested that 
baroreflex gain was facilitated by AVP (Cowley et al, 
1984), but inconsistent results have been obtained in 
human subjects (Ebert, Cowley & Skelton, 1986; Aylward et 
al, 1986). It is clear however, that small changes in 
systemic vascular resistance may occur after infusion of 
small doses of AVP (Ebert et al, 1986), and that posture 
may affect these changes (Simpson et al, 1986). Whether 
these buffering changes are neurally mediated, or mediated
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by vasodilatation in other vascular beds, perhaps by 
activation of V2 receptors (Williams, Lightman & 
Leadbetter, 1986) is not clear.
1.3.4 Vasopressin in diabetes mellitus
Although an elevation of blood glucose concentration in 
normal man is an ineffective stimulus to thirst or 
vasopressin secretion (Zerbe & Robertson, 1983), it is 
apparent that in poorly controlled insulin dependent 
diabetes mellitus, characterised by polyuria, polydipsia 
and raised plasma osmolality, marked increases in plasma 
vasopressin are observed in diabetic ketoacidosis (Walsh, 
Baylis & Malins, 1979), non-ketotic hyperglycaemia (Zerbe, 
Vinicor & Robertson, 1979) and during acute insulin 
withdrawal (Milles, Baylis & Wright, 1981). The cause of 
this hypervasopressinaemia may in part be secondary to 
non-osmotic factors such as hypovolaemia or nausea, but 
its discovery has stimulated work on the physiology of 
both osmotic and non-osmotic vasopressin release in the 
diabetic state.
Osmotic release
Zerbe, Vinicor & Robertson (1985) performed both
/
hypertonic saline and hypertonic glucose infusions in 
insulin-dependent diabetics and found that the threshold 
plasma sodium level at which plasma vasopressin levels 
rise was lower than in normals. They also found that
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hypertonic glucose had no effect on AVP levels in both 
groups, despite higher basal levels in the diabetics. 
Thompson et al (1988), however, found no such shift in the 
plasma sodium threshold. Their diabetics however, were 
euglycaemic during the saline infusion, and it seems clear 
that the differences obtained were probably because of 
this. Acute moderate hyperglycaemia during this study 
had no effect on AVP levels, suggesting that other factors 
must influence the elevation of AVP in uncontrolled 
diabetes.
A more recent study by the same group (Thompson, Davis & 
Baylis, 1989) looked at this question, by performing 
hypertonic saline infusions in diabetics rendered either 
euglycaemic or hyperglycaemic by a clamping technique. 
They found that the hyperglycaemic state was indeed 
responsible for the shift in plasma sodium threshold to 
the left. It is known that hypovolaemia lowers the 
osmotic threshold for AVP release (Robertson, Aycinena & 
Zerbe, 1982), but there was no evidence for this in their 
data.
A further explanation for this phenomenon could, be the 
theory that insulin deficiency alters the function of 
osmoreceptor cells. It is thought that insulin promotes 
transport of glucose into the osmoreceptor cells, 
preventing the development of an osmotic gradient
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necessary to change cellular volume and stimulate AVP 
release (Baylis & Robertson, 1980). If insulin levels 
are low, high glucose levels may be able to create an 
osmotic gradient which then stimulates AVP release. 
Evidence supporting this view comes from a study (Vokes, 
Aycinena & Robertson, 1987) in which insulin-deficient 
diabetic subjects had greater incremental rises of plasma 
AVP to osmotic stimuli than healthy controls. The 
differences appear to occur only during severe 
insulinopenia, and result from an increase in sensitivity 
of the osmoreceptors, rather than the set-point. In a 
group of 10 type I diabetics, Grimaldi et al (1988) found 
that elevating blood glucose from a mean of 12.4 mmol 1“1 
to 47.0 mmol 1-1 raised plasma AVP from a (high) basal 
value of 5.6 pg ml“l to 7.7 pg ml”!. They have 
postulated a direct effect of glucose on osmoreceptors, 
but the fact that both basal and post-infusion blood 
glucose levels were much higher than in other studies 
implies that non-osmotic influences were probably 
responsible for the raised plasma AVP levels.
In general, therefore, the evidence suggests that 
hypothalamic control of osmoregulated vasopressin 
secretion appears to be normal in diabetics without 
evidence of autonomic neuropathy. I will present 
evidence in chapter 4 on whether this is so in the 
presence of clear autonomic dysfunction.
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Non-osmotic release
What evidence there is in diabetics without autonomic 
neuropathy suggests that postural and hypovolaemic stimuli 
to AVP release are normal. In a well defined group of 
insulin-dependent diabetics without autonomic neuropathy, 
volume depletion by fruseraide appropriately raised AVP 
levels by over fifty per cent (Grimaldi et al, 1985). 
Another study found that in four out of five such 
diabetics plasma AVP levels rose after standing for two 
hours (Cignarelli et al, 1986). In a more recent paper, 
using rather less well characterised type II diabetics who 
were also hypertensive, no significant changes in plasma 
AVP levels were seen after thirty minutes of standing 
(Saad et al, 1988).
The only other non-osmotic stimulus to AVP release in 
diabetics yet studied is that of insulin-induced 
hypoglycaemia. Plasma AVP levels rose significantly 
higher in a group of type I diabetics than in matched 
normal controls (Thompson et al, 1989). As mentioned in 
1.3.2, the mechanism by which hypoglycaemia releases AVP 
is not yet known
1.3.5 Vasopressin in disorders of autonomic function
Early in the course of investigation into vasopressin, it 
was apparent that interference with the autonomic nervous
system produced effects. Verney (1947) demonstrated a 
heightened antidiuretic effect of electrical flank 
stimulation in a dog which had been surgically denervated. 
The antidiuresis could be countered by an infusion of 
tyramine or noradrenaline. Later work (Schrier & Berl, 
1972), again in dogs, showed that bilateral cervical 
vagotomy caused an AVP-mediated antidiuresis secondary to 
interruption of afferent neural pathways, since efferent 
blockade of parasympathetic pathways with atropine did not 
influence renal water excretion. Thus increased AVP
levels were produced by damage to the parasympathetic 
pathways.
In the intervening period, it was shown that in human 
subjects, the pressor effect of AVP could be demonstrated 
in the presence of autonomic problems. Wagner & 
Braunwald, in 1956, caused blood pressure to rise in both 
patients with idiopathic orthostatic hypotension and in 
subjects pretreated with a ganglion-blocking agent.
It is clear, therefore, that in crude terms both the 
release of AVP and its effects in vivo are affected by 
autonomic dysfunction. In this section I will attempt to 
outline the current knowledge of how AVP release and its 
actions differ from the normal state in the presence of 
damage to the autonomic nervous system, with reference to 
some of the relevant animal work, to work on subjects with
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primary disorders of the autonomic system, to 
tetraplegics, subjects with cardiac transplants, and 
finally in diabetics with autonomic neuropathy.
Animal considerations
Recent work in animals has provided evidence that AVP may 
play a central role in control of blood pressure despite 
its lack, of pressor effect in physiological doses, and 
that it exerts powerful effects on central nervous 
mechanisms concerned with cardiovascular regulation. 
Montani et al (1980) showed in dogs that mean arterial 
pressure (MAP) did not change when AVP was infused at 
physiological doses because, despite large increases in 
total peripheral resistance (TPR), cardiac output fell to 
compensate. The effects were in part attributed to a 
direct action of AVP on baroreflex activation. Cowley 
et al (1984) performed elegant studies on surgically 
denervated dogs which suggested that AVP enhanced carotid 
reflex gain by more than two fold when intrasinus pressure 
fell below the equilibrium point. A vagally mediated 
bradycardia was produced by AVP which buffered the 
increase in pressure by reducing cardiac output. Further 
evidence for an important action of AVP in denervation 
came from work which showed that both AVP and the 
sympathetic nervous system interact in the presence of 
vagal deafferentation to produce a pressor response 
(Hasser et al, 1984). In the presence of bilateral vagal
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cold block, conscious dogs both with and without 
denervation of the carotid sinus were given both a 
ganglion blocking agent and a specific vasopressin 
antagonist. It was shown that in 'intact' dogs the AVP 
antagonist augmented the hypotensive effect of the 
ganglion blocker but that no intrinsic hypotensive effect 
was produced. When the sinoaortic denervated animals 
were studied, the AVP antagonist produced a consistent 
hypotensive effect, which was heightened by ganglion 
blockade. The authors suggested that AVP thus modulates 
the haemodynamic changes associated with vagal 
deafferentation. It it also clear that in dogs, levels 
of AVP which have no effect on arterial pressure, may have 
profound effects on central venous pressure which may 
affect cardiopulmonary afferents which act to offset a 
rise in arterial pressure (Bie & Warberg, 1983). Further 
work in both dogs and other animals suggests an interplay 
between the renin-angiotensin, sympathetic nervous system 
and AVP in the presence of denervation. In dogs, data 
suggests that AVP plays an important role in blood 
pressure maintenance following haemorrhage. Despite 
activation of the renin-angiotensin system following mild 
haemorrhage, a dramatic fall in blood pressure was seen 
after administration of a vasopressin antagonist (Schwartz 
& Reid, 1981). AVP release following haemorrhage in 
cardiac denervated dogs has also been shown to be reduced 
(Wang et al, 1983), suggesting an important role for
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cardiac volume receptors in AVP release. No significant 
changes in haemodynamics were seen between the denervated 
dogs and controls, suggesting that sensitivity to AVP may 
be heightened under these circumstances.
Total ablation of the CNS (Cowley & Barber, 1983) and 
total chemical autonomic blockade (Pullan et al, 1980) 
have also been shown to result in increased pressor 
sensitivity to AVP.
Therefore, in the dog, the role for AVP appears to have 
been well established. In rats, there are considerably 
more technical problems in both methods used to study them 
and in interpreting the results obtained, although much of 
the anatomical work delineating central pathways for AVP 
release has been gathered from them (Sawchenko & Swanson, 
1981; Sawchenko & Swanson, 1982). The difficulties 
inherent in interpreting the studies on animals are 
outwith the scope of this thesis, and have been 
comprehensively reviewed elsewhere (Bennett & Gardiner, 
1985; Bennett & Gardiner, 1986).
Denervation in humans
In 1956 Wagner & Braunwald showed in man that infusion of 
AVP could indeed have major pressor effects in the 
presence of autonomic problems. Both> volunteers,
pretreated with ganglion blockers, and patients suffering
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from idiopathic orthostatic hypotension demonstrated this 
effect. Later work confirmed this. This condition is 
also known as Shy-Drager syndrome, or progressive 
autonomic failure (PAF) with or without multiple system 
atrophy (MSA). These patients have degeneration of the 
sympathetic nervous system and often have gross 
pathological and neurochemical damage (Spokes, Bannister & 
Oppenheimer, 1979) to the locus coeruleus in the brainstem 
(Bannister, 1983). Work in rats has demonstrated that 
the noradrenergic projection from the locus coeruleus to 
the periventricular zone of the paraventricular nucleus is 
of great importance in the arginine vasopressin response 
to cardiovascular stimuli (Lightman, Todd & Everitt,
1984).
Two studies in patients with PAF have found defective 
release of AVP to the stimulus of head-up tilt, despite 
marked hypotension which would normally cause a marked 
rise in AVP levels (Puritz et al, 1983; Zerbe, Henry & 
Robertson, 1983). These patients have been demonstrated 
to have normal release of AVP to osmotic stimulation by 
hypertonic saline infusion (Williams, Lightman & 
Bannister, 1985), indicating that an afferent defect below 
the hypothalamic level, perhaps at the locus coeruleus is 
responsible for the subnormal release of AVP. 
Interestingly, a significant rise in mean blood pressure 
was seen in this group, which at least in part may have
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been caused by sensitivity to the pressor effects of AVP. 
Certainly since Wagner & Braunwald's original report, 
other studies have confirmed the phenomenon, which also 
occurs in response to lysine vasopressin (Bannister, 
Ardill & Fentem, 1969). Mdhring et al (1980), in two
such patients found that physiological levels of AVP 
produced a pressor response which was maximal early in the 
infusion. Williams et al (1986) performed stepwise 
infusion of AVP in eight subjects with PAF and found 
marked pressor effects at levels within the physiological 
range. In contrast to the animal work, no effects of 
interaction with the cardiac baroreflex were observed. 
The authors suggested that receptor changes may occur in 
the presence of denervation and that studies in groups of 
patients with denervation of different aetiologies may 
help to illuminate whether this is so.
One such group of patients are tetraplegics, who like the 
PAF patients have an interruption of their sympathetic 
outflow as well as a spinal cord lesion, but in contrast 
have normally functioning glossopharyngeal and vagal 
cranial nerves and normal central catecholaminergic 
pathways. Three papers provide much insight into this 
matter. Di Pette et al (1984) looked at changes in AVP, 
blood pressure and heart rate for twenty minutes following 
the injection of a hyperosmolar radiocontrast agent for 
intravenous urography. They found a rise in blood
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pressure and AVP levels in a tetraplegic group, but not in 
their control subjects. The changes were maximal in the 
first five minutes and returned towards normal at the end 
of the study. They therefore had heightened AVP release 
to an osmotic stimulus (though non-osmotic influences may 
have contributed to this) and perhaps an increased pressor 
responsiveness to AVP. Sved, McDowell & Blessing (1985) 
studied the release of AVP to head-up tilt in their 
patients, and found a four-fold increase in plasma AVP 
levels to rapid tilt to 70°, in keeping with the marked 
hypotension observed during the procedure. In both 
reports, basal AVP levels were normal. The most
compelling work (Poole et al, 1987) studied eight 
tetraplegics by hypertonic saline infusion, head-up tilt 
and stepwise infusion of AVP. In contrast to Di Pette et 
al, they found no significant differences compared with 
controls in plasma AVP levels following hypertonic saline, 
but found a marked rise in mean arterial pressure. 
Following head-up tilt, AVP levels rose much higher than 
controls because of the hypotensive stimulus. Infusion 
of arginine vasopressin at physiological levels produced a 
marked rise in blood pressure in the tetraplegics. In 
contrast to the patients with PAF, the tetraplegics showed 
a marked bradycardia, presumably mediated via the 
baroreflex and intact vagal outflow, an action of AVP 
known to occur in animals (Courtice et al, 1984).
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Cardiac transplant patients are a little studied group. 
Only one study has looked at AVP in such patients (Drieu 
et al, 1986). As hypertonic saline infusion was 
considered unethical in these mainly hypertensive 
patients, water loading was performed and was suggestive 
of normal osmotic control. Basal AVP levels, however, 
were raised, and no increase in plasma AVP levels was seen 
after moderate volume depletion with frusemide. This 
suggests that cardiac receptors and innervation play a 
dominant role in the AVP response to volume depletion in 
man.
Surprisingly, little work on AVP release or its effects 
has been performed in diabetics with autonomic neuropathy. ' 
No work has addressed whether osmotic release of AVP in 
these patients is normal or not. Autonomic neuropathy in •' 
diabetics is considered to be a disease which does not > 
affect the central nervous system, although vascular ■ 
changes are well documented in the brains of longstanding 
diabetics (Reske-Nielsen, Lundbaek & Rafaelsen, 1965).
It may well be important therefore to see whether osmotic 
release of AVP following hypertonic saline infusion is 
abnormal or not, as hypothalamic damage could affect its 
secretion. No studies in the literature have addressed 
this question, but I will present my findings from such a 
study in chapter 4.
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The responses of AVP to orthostatic and/or volume stimuli 
in diabetic autonomic neruopathy is another area in which 
there is a paucity of data. Zerbe, Henry & Robertson 
(1983) studied two patients, with diabetic autonomic 
neuropathy (DAN +ve) amongst a group of eighteen subjects 
with various causes of orthostatic hypotension following 
the stimulus of head-up tilt, initially to sixty degrees, 
and progressively to ninety degrees. Their results were 
conflicting. One diabetic responded appropriately to 
tilt with a rise in plasma AVP, and the other, despite a 
sixty per cent fall in mean arterial pressure, had only a 
small increase in AVP levels.
Grimaldi et al (1985) used volume depletion induced by 
intravenous frusemide as a stimulus for AVP release in a 
well characterised group of sixteen DAN +ve patients and 
compared their responses with seventeen DAN -ve patients. 
In both groups plasma volume (estimated from the rise in 
plasma protein) fell by approximately twelve per cent, 
while MAP fell only in the DAN +ve patients (by thirteen 
and a half per cent). Plasma AVP levels remained 
unchanged after sixty minutes in the DAN +ve subjects, but 
had risen by over fifty per cent in the DAN -ve group. 
Interestingly, one cardiac transplant patient was also 
studied. No rise in plasma AVP was seen, despite a 
similar fall in plasma volume. This subject maintained
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his blood pressure throughout the study.
Further evidence for an afferent defect in the pathways 
controlling AVP release in diabetic autonomic neuropathy 
comes from Cignarelli et al (1986). In four out of nine 
diabetics affected by autonomic neuropathy, plasma AVP 
failed to increase after five minutes of standing, 
although two hours after standing plasma AVP levels had 
risen in one of them. Two of the diabetics had no blood 
pressure fall on standing, and may therefore not have 
provided a sufficient hypotensive stimulus to AVP release. 
Evidence for an afferent defect in AVP release therefore 
does exist in diabetics with autonomic neuropathy, but 
responses seem to be variable, perhaps for methodological 
reasons. In chapter five I will present further evidence 
for an afferent defect, using the well established 
technique of head-up tilt.
No studies exist in the human literature examining the 
effects of infused AVP, either in physiological or 
pharmacological doses in diabetics with autonomic 
neuropathy, although one study in rats rendered diabetic 
by streptozotocin has suggested a decreased pressor 
responsiveness to vasopressin following ganglion blockade 
(Hebden, Bennett & Gardiner, 1987).
Only one study has indirectly suggested that AVP may play
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an important role in blood pressure maintenance in 
diabetics with autonomic neuropathy (Saad et al, 1988). 
The only evidence of autonomic dysfunction in this group 
of type II diabetics with hypertension was postural 
hypotension. After dosing with a receptor antagonist, 
a sub group had a very marked hypotensive response. No 
details of renal function or other diabetic complications 
were given and their conclusions are perhaps overstated 
from the data presented.
There is therefore no clear evidence for the role that AVP 
may play in diabetics with autonomic neuropathy. If the 
theory devised from work on tetraplegics and patients with 
progressive autonomic failure, that autonomic damage leads 
to changes in V^-receptor sensitivity" is true, one might
expect diabetics with autonomic dysfunction to display 
similar changes, in keeping with work on supersensitivity 
to catecholamines (Hilsted et al, 1987). I will present 
evidence to confirm this theory in chapter six.
1.4 AIMS OF THIS THESIS
As already discussed in this introductory chapter, this 
thesis presents studies on different aspects of 
denervation in diabetic autonomic neuropathy.. In chapter 
3 data is presented from a study in which autonomic
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neuropathy in diabetes is used as a model to study heart 
rate changes (Bi-adrenoreceptor mediated) and changes in 
physiological tremor (B2 ~adrenoreceptor mediated) which 
occur after dosing with beta-adrenoreceptor blocking drugs 
which possess partial agonist activity. As well as 
determining the cardioselectivity of the drugs' partial 
agonism, the changes in heart rate should give an 
indication of the denervated state which prevails in the 
diabetics studied. By comparing these changes with those 
which occur both in normal subjects and in other forms of 
denervation, it may be possible to infer whether the heart 
rate changes in diabetic autonomic neuropathy reflect B^- 
adrenoceptor denervation supersensitivity, as may be found 
in both animals (Barrett & Carter, 1970) and in autonomic 
failure (Man in't Veld & Schalekamp, 1981).
Chapters 4, 5 and 6 are studies which follow on from work 
performed in progressive autonomic failure and 
tetraplegia. Chapter 4 examines whether autonomic 
neuropathy affects osmotic control of vasopressin 
secretion in diabetes. This is an important point to 
address, as the interpretation of the results presented in 
chapter 5, where endogenous AVP secretion is stimulated by 
head-up tilt, and in chapter 6, where physiological doses 
of AVP are infused to assess pressor responsiveness, may 
be affected if abnormal osmotic secretion is present.
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By comparing and contrasting these studies with work 
performed in the other forms of autonomic dysfunction, it 
should be possible to obtain information about the effect 
of diabetic autonomic damage on the neural pathways 
involved in vasopressin release, on hypothalamic and 
posterior pituitary function, and on end-organ (vascular) 
effects of vasopressin. By placing this work in the 
perspective of the current literature, I hope to provide 
some insight into the degree of autonomic nervous damage 
that diabetes can cause.
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CHAPTER 2
METHODS AND MATERIALS
2.1 Subjects
The diabetic subjects studied in this thesis were drawn 
from the diabetic and dietetic outpatient department in 
the Royal Infirmary of Edinburgh, which looks after 
patients from the city of Edinburgh and other parts of 
Lothian region. Because of the research interests of the 
clinic, large numbers of patients each year are screened 
for signs and symptoms of peripheral and autonomic 
neuropathy. With the exception of the patients mentioned 
in my declaration, all the subjects were seen by me after 
screening and entered into the studies.
As different subjects were used in the different studies, 
for convenience details are given in the individual 
chapters.
2.2 Cardiovascular autonomic reflex tests
The classification of autonomic status in all the subjects 
studied in this thesis depends upon a battery of five 
cardiovascular autonomic reflex tests which are simple, 
non-invasive, reproducible and distinguish clearly between 
normal and abnormal results. Three tests are based on
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measurements of heart rate responses: the Valsalva
manoeuvre, deep breathing and standing. The other two 
are measurements of blood pressure responses to standing 
and to sustained handgrip. The heart rate responses are 
indicative of cardiac parasympathetic integrity, while the 
blood pressure changes are only abnormal with more 
extensive and widespread (extracardiac) sympathetic damage 
(Ewing, 1983; Watkins & Edmonds, 1983). The autonomic 
pathways involved in these reflexes are complex. Both 
parasympathetic and sympathetic innervation plays some 
part in all five tests, and while a division into 
parasympathetic and sympathetic tests is clinically 
convenient, this does not strictly reflect all the complex 
underlying physiological mechanisms. In this thesis, 
therefore, I will refer only to heart rate and blood 
pressure tests, rather than being dogmatic about the 
precise autonomic innervation of each reflex test. These 
tests are further outlined in Ewing (1978), Ewing & Clarke 
(1982), Ewing (1983) and Ewing et al (1985).
1. Valsalva manoeuvre (Valsalva ratio)
The subject sits quietly and then blows into a mouthpiece 
at a pressure of 40 mmHg for 15 seconds. The heart rate 
normally increases during the manoeuvre, followed by a 
rebound bradycardia after release. The ratio of the 
longest R-R interval shortly after the manoeuvre to the 
shortest R-R interval during the manoeuvre is then
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measured. The result is routinely expressed as the
Valsalva ratio, as the mean ratio from three successive 
Valsalva manoeuvres.
/
2. Heart rate response to standing up (30:15 ratio)
The subject lies quietly on a couch and then stands up 
unaided. Normally an immediate increase in heart rate
occurs that is maximal at about the 15th beat after 
starting to stand, followed by a relative bradycardia, 
maximal around the 30th beat. This can be quantified as 
the 30:15 ratio, which is the ratio of the longest R-R 
interval around the 30th beat to the shortest R-R interval 
around the 15th beat.
3. Heart rate response to deep breathing (R-R variation)
The subject sits quietly and then breathes deeply and 
evenly at 6 breaths per minute. The maximum and minimum 
heart rates during three successive breathing cycles are 
taken to give the maximum-minimum heart rate.
4. Blood pressure response to standing up
The blood pressure is measured using a standard 
sphygmomanometer while the subject is lying down, and 
again after standing up. The difference in systolic 
blood pressure is taken as the measure of postural blood 
pressure change.
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5. Blood pressure response to sustained handgrip
Handgrip is maintained at 30% of the maximum voluntary 
contraction using a handgrip dynamometer (Tephcotronics 
Limited, Edinburgh) up to a maximum of five minutes, and 
the blood pressure measured each minute. The difference 
between the diastolic blood pressure just before release 
of handgrip, and before starting, is taken as the measure 
of response.
Tests 1, 2 and 3 reflect heart rate responses and were 
previously referred to as “parasympatheticM (PS) tests, 
while tests 4 and 5 measure blood pressure responses and 
were previously referred to as "sympathetic" (S) tests.
The results of these tests are grouped into three 
categories - normal, borderline or abnormal. If all 
tests are normal or one borderline, they are referred to 
as normal (N); early involvement (E) if one of the three 
heart rate tests are abnormal or two borderline; definite 
involvement (D) if two or more of the heart rate tests are 
abnormal; and severe (S) where two or more of the heart 
rate tests are abnormal, plus one or both of the blood 
pressure tests are abnormal or both borderline (Ewing et 
al, 1985). Each subject can also be given an "autonomic 
score" by scoring each test as normal (0), borderline (1), 
or abnormal (2), giving a total score for the five tests 
of 0 (normal) to 10 (most abnormal). The repeatability
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of these tests has been well established (Ewing et al,
1985).
Where a test is omitted, for example the Valsalva ratio 
when there is untreated proliferative retinopathy, the 
score is given out of eight.
These tests are summarised in table I.
During the period of time this work was performed, these 
tests were carried out by using an on-line BBC 
microcomputer linked to an ECG recorder, using software 
specifically designed for the purpose ("AUTOCAFT" - UnivEd 
Technologies Limited, Edinburgh). This system allows 
individual R-R intervals to be measured to an accuracy of 
± 1 0 ms, and thus allows very precise measurement of both 
R-R variation, and indeed heart rate.
Retinopathy was assessed by indirect ophthalmoscopy, after 
mydriasis by Tropicamide 0.5% eyedrops, and graded as 
absent (-), background (B), exudative (E) or proliferative 
(P)-
Proteinuria was assessed by Albustix (Ames Division, Miles 
Limited, Stoke Poges, UK) and classified according to the 
manufacturer's instructions.
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2.3 Heart rate in all studies performed in Edinburgh in 
this thesis was recorded using the microcomputer system to 
average heart rate over a period of time (five minutes in 
chapter 3, ten seconds for each measurement point in 
chapters 4, 5, and 6 ).
24 hour heart rate (chapter 3) was measured using a 
standard ambulatory ECG technique ("Tracker" - Reynolds 
Medical Company Limited), which allows 'real-time' 
recordings to be made, with an event button to mark 
specific points in the recording. The tapes thus 
obtained were replayed through a Pathfinder high speed 
arrhythmia analyser (Reynolds Medical Company Limited) at 
exactly 60 times the original recording speed to generate 
an output representing heart rate.
Blood pressure (chapters 4, 5 and 6 ) All blood pressure 
recordings in Edinburgh were made using a Hawksley random 
zero sphygmomanometer, Korotkoff phase V being taken as 
the diastolic pressure. Mean blood pressure was
calculated by adding one-third of the pulse pressure to 
the diastolic pressure. The normal controls in chapter 
six had blood pressure measurements made with an automatic 
sphygmomanometer (Sentron, Bard Biomedical).
Physiological tremor (chapter 3) Changes in
physiological tremor produced by beta-adrenoreceptor
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blocking or stimulating agents can be used as a model of 
beta2 ~adrenoreceptor activity. B2 ~adrenoceptor agonists 
such as isoprenaline increase tremor and differences 
between Bi-selective and non-selective B-adrenoceptor 
blocking drugs can be detected in man (Arnold & McDevitt, 
1984).
Physiological tremor was measured using a piezo-electric 
accelerometer (Vibro-Meter Corp, Boston, USA - sensitivity 
in the vertical plane 10.05 mVg-*) attached by a tubigauze 
(Seton Medical, UK) bandage to the outstretched index 
finger of the right hand with the arm supported at the 
elbow on a firm laboratory bench. The output from the 
transducer was recorded onto magnetic tape via the 
vibration module of an Instrumentation Cassette Recorder 
(Type DA 1442 Data Acquisition Limited, Stockport, UK). 
The magnetic tape signal was subjected to a fast Fourier 
Transformation using a PDP11 computer and a power spectrum 
in the frequency 0 - 30 Hz obtained.
Tilt studies (chapter 5) were performed using a modified 
operating table with a footrest at the base. Tilt was 
achieved manually over a period of 15 seconds.
Infusion studies (chapters 4 and 6 ) were performed using a 
standard intravenous infusion pump (IMED 960, Abingdon, 
England).
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2.4 BIOCHEMICAL VARIABLES
Arginine vasopressin - All samples for plasma AVP levels 
were collected into lithium heparin tubes, immediately 
centrifuged, and the separated plasma deep frozen for 
later analysis at the Westminster Hospital. Samples were 
stored for less than two months at -20°C before SEP-Pak 
extraction and estimation of AVP by radioimmunoassay 
(Williams, Carter & Lightman, 1985).
Plasma samples (1 ml) were acidified with 3 ml 0.1M formic 
acid and extracted using a modification of the SEP-Pak 
method. Octadecasilyl silica columns (C18 Sep-Paks, 
Waters Associates, Norwich, England) attached to a 
multichannel pump (Watson-Marlow, Falmouth, England) were 
first regenerated with 95% methanol-5% 0.1M formic acid (3 
ml) followed by 0.1M formic acid (3 ml), and the acidified 
samples were passed on to the columns at 1 ml per minute 
and washed with 0.1M formic acid (3 ml). Elution with 
95% methanol-5% 0.1M formic acid (3 ml) was followed by 
solvent extraction in a vacuum centrifuge (Speed Vac 
Concentrator, Uniscience, London, England). The residue 
was taken up in 500 ul RIA buffer (0.1M Tris acidified to 
pH 7.4 with HCL and containing 2g l” 1 BSA) for subsequent 
assay of AVP in 100 ul duplicates. Extraction yield for 
AVP, calculated from extracting 125i_iaken ecj ^VP added to
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plasma was 94 ± 2% (mean ± SD, n = 10). AVP was measured 
by a highly specific and sensitive RIA using 100 ul each 
of: (1) First International Standard for AVP, (2) 125j_
labelled AVP (3000-4000 cpm), and (3) specific AVP 
antiserum at a final dilution of 1:300,000. Incubation 
was carried out for 48 h. Bound tracer was separated 
from the free fraction by precipitating with chilled 
ethanol,, centrifuging, and decanting the supernatant. 
Fifty per cent inhibition of tracer binding occurred with
2.5 fmol standard AVP.
The coefficients of variation for control AVP samples (2 
fmol) were 6 % (intra-assay) and 15% (inter-assay).
Plasma adrenaline and noradrenaline - These samples were 
also immediately centrifuged, the plasma deep frozen and 
stored in liquid nitrogen, and later assayed by the 
radioenzymatic method of Da Prada and Zurcher (1976). 
This assay is based on the 3-O-raethylation of 
catecholamines by the enzyme catechol-O-methyl-transferase 
(COMT) in the presence of 3H-S-adenosylmethionine (3H- 
SAM). Labelled O-methylated products are transformed to 
less polar complexes by adding sodium tetraphenylborate 
(TPB) and thereafter extracted into diethyl ether. The 
products of the reaction are separated by thin-layer 
chromatography. Methoxytyramine (MT) derived from 
Dopamine 3-O-methylation, is eluted and the radioactivity
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measured. Metanephrine and normetanephrine is further 
oxidised to vanillin and its radioactivity is counted 
after extraction. Aliquots of pooled normal plasma were 
analysed concurrently (mean 2.5 nmol I”*, CV 5.4%).
Plasma renin activity was measured by a modification 
(Roulston & MacGregor, 1978) of the method of Boyd et al 
(1969). , Blood is sampled and put into tubes containing
EDTA (2.5 mg EDTA per ml blood). The tubes are 
centrifuged at 2000 x g for 15 minutes at 4°C. The 
supernatant plasma is then frozen at -20°C until assay.
The plasma was thawed, but the temperature not allowed to 
exceed 4°C. It was then mixed with an equal volume of 
0.1 molar potassium citrate/citric acid buffer at pH 5.7 
followed by 0.46 molar 8-hydroxyquinolone (40 ul per ml of
plasma) and 80 ul per ml of plasma of a saturated
ethanolic solution of phenylraethylsulfonylfluoride (PMSF). 
After thorough mixing, one portion of the sample was 
incubated at 37°C for three hours to generate angiotensin 
I whilst the other portion was maintained at 0°C in an ice 
bath. Radioimmunoassay of angiotensin I was then 
performed by the method of Boyd et al on both the 
incubated and unincubated portions; plasma renin activity 
(or angiotensin I generation rate) being calculated as a 
direct fraction of the difference in angiotensin I
concentration in the two portions (after correction for
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incubation time and plasma dilution). Interassay
coefficients of variation (CV) were between 9 and 12.6% 
(Roulston & MacGregor, 1978).
Plasma aldosterone was measured by a commercially 
available radioimmunoassay kit (CIS UK Limited, High 
Wycombe, Bucks). The principle of this assay is based on 
the competition between the labelled aldosterone and 
aldosterone contained in standards or specimens to be 
assayed, for a fixed and limited number of antibody 
binding sites. After incubation, the amount of labelled 
aldosterone bound to the antibody is inversely related to 
the amount of unlabelled aldosterone present in the 
sample. The method adopted for B/F separation is based 
on the use of the antibody-coated tubes, where the 
antibody is fixed on the tube walls by Catt's method. 
The interassay CVs were between 8 and 10% (data on file, 
CIS (UK) Limited).
Plasma glucose was measured by a standard glucose oxidase 
technique. Plasma sodium was measured by flame
photometry (Corning 435 flame photometer) and plasma 
osmolality by an Advanced Digimatic Osmometer model 3DII. 
Haematocrit was obtained from the mean of three micro- 
haematocrit measurements.
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2.5 STATISTICAL METHODS
Chapter 3
The 24 hour heart rate measurements were analysed over 
three periods. Mean hourly heart rates and mean heart 
rate (mean of the mean hourly heart rates) within each of 
the three periods have been used in the analysis. The 
physiological tremor data was transformed into natural 
logarithms for statistical analysis as its distribution 
was non-normal and the transformed data was displayed as 
power spectra over the range 0 - 30 Hz. To give an 
overall measure of tremor for each patient, the log 
transformed readings were summed over the frequency range 
0 - 30 Hz ('area under the curve') and this measurement 
was used in the analysis. These results and the resting 
heart rate and glucose measurements were subjected to an 
analysis of variance technique. Overall treatment 
significance was assessed by an F test after which, if 
significant differences were found (p < 0.05), pairs of 
treatments were compared using a two sided Student's t- 
test with the residual mean square estimating the standard 
error. The level of significance for the t-tests was p < 
0.05, calculated from the least square estimates of the 
means.
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Chapters 4, 5 and 6
Data analysis was carried out using a statistical software 
package (Minitab Statistical Package). In chapters 4 and 
5, paired Student's t tests were performed on all baseline 
values within each group. As there were no significant 
differences between the -10, -5 and 0 minute measurements 
within the three groups, baseline measurements were taken 
as the 0 .minute readings. Areas above and below baseline
values over the next 1 2 0 minutes were then calculated for 
each variable, and used to determine differences from 
baseline. An analysis of variance with a simultaneous 
comparison of the three groups was first performed on the 
baseline and the area under the curve values. Where 
significant differences were observed, a further analysis 
was performed using a Student's t test to detect which 
pairs of groups differed significantly. Significant
changes from baseline during the 1 2 0  minute infusion 
period in chapter 4 were tested by calculating a 't' 
statistic for each area under the curve value for each of 
the groups. Linear regression equations were calculated 
for each individual for the relationships between plasma 
osmolality and AVP, and plasma sodium and AVP, during the 
saline infusion. The individual regression coefficients, 
slopes and intercepts were then used in a subsequent 
analysis to compare groups.
*
In chapter 6 , baseline values at -10, -5 and 0 minutes
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were compared within each group using an analysis of 
variance. The AVP levels at the different infusion rates 
were compared as follows. Regression coefficients from 
the logarithmically transformed plasma AVP levels on log 
infusion rates over the range of 0.2 pmol min“^kg“  ^ to 5 
pmol min'^kg-l were calculated for each subject, and the 
derived variables compared between the three treatment 
groups using an analysis of variance.
In view of the slightly different intermediate infusion 
rates used in the normal and diabetic groups, it was 
considered more appropriate to make statistical comparison 
of the results using 'area under the curve' measurements 
rather than maximum blood pressure responses. 'Areas 
under the curve' (AUC) were, therefore calculated for the 
heart rate and mean blood pressure responses for each 
subject over the same range of infusion levels, and the 
differences between the three groups compared using an 
analysis of variance. Omission of the lowest AVP 
infusion rate meant that this small AVP dose was not given 
a disproportionate emphasis in the analysis.
2.6 Ethical aspects
Permission for all the studies presented in this thesis 
was granted by the appropriate local Hospital Ethical 
Advisory Committees, and all subjects gave their written 
informed consent before taking part.
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CHAPTER 3
EFFECTS OF B-ADRENOCEPTOR BLOCKADE ON HEART RATE AND 
PHYSIOLOGICAL TREMOR IN DIABETICS WITH AUTONOMIC 
NEUROPATHY: A COMPARATIVE STUDY OF EPANOLOL,
ATENOLOL AND PINDOLOL
3.1 INTRODUCTION
As outlined in chapter 1.2.5, some B-adrenoceptor blocking 
agents are known to be partial agonists at the B- 
adrenoceptors, for example practolol and pindolol. It 
is, however, unclear, especially in man, whether the 
stimulant effect of a non-selective B-adrenoceptor
blocking drug with PAA is at the B^-adrenoceptor, 8 2 - 
adrenoceptor, or both, or whether a B^-selective partial 
agonist produces stimulation only at the B^-adrenoceptor. 
To answer this question a study measuring both B^- and B2 - 
adrenoceptor function is required in which a non-selective 
and a B^-selective adrenoceptor blocking agent, both with 
PAA, are compared in the same subjects.
The demonstration of partial agonism of B-adrenoceptor
blocking drugs at the B^-adrenoceptor in animal models
requires that the heart is surgically denervated and the 
animals depleted of catecholamines by syrosingopine
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(Barrett & Carter, 1970). This situation may be
analogous in man to diabetic patients with severe diabetic 
autonomic neuropathy (Watkins & Edmonds, 1983). 
Certainly in autonomic failure from other causes an 
increase in heart rate has been noted when B-adrenoceptor 
blocking agents with PAA were given (Man in't Veld & 
Schalekamp, 1981). If B-adrenoceptor blocking agents 
with PAA are given to such diabetics, increases in heart 
rate might occur due to Bi-adrenoceptor stimulation.
Physiological tremor has been shown to involve peripheral 
B-adrenoceptors (Marsden et al, 1967). More recently, 
increase in physiological tremor induced by 
sympathomimetic amines has been thought to be due to B2 - 
adrenoceptor stimulation (Arnold & McDevitt, 1984), and 
provides a model for measurement of B2 ~adrenoceptor 
function.
Diabetics with extensive autonomic neuropathy may 
therefore provide a model in man for investigating B- 
adrenoceptor blocking drugs with PAA. The aim of this 
study was to determine the effects of three different B- 
adrenoceptor blocking drugs: epanolol (Bi-selective with
PAA (Pringle et al, 1986)), atenolol (Bi-selective with no 
PAA) and pindolol (non-selective with PAA) on heart rate 
and physiological tremor in diabetics with autonomic 
neuropathy. Their selectivity or otherwise has been
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established in man (Harry, 1977; Aellig, 1982; Norris et 
al, 1984; Pringle et al, 1986). In animals, atenolol has 
been shown to have no PAA, while epanolol and pindolol do 
(Harry, Knapp & Linden, 1974; Bilski, Robertson & Wale, 
1979; Smith et al, 1983). Pindolol stimulated the heart 
rate of catecholamine depleted rats (a Bi effect) to a 
maximum of 120 beats min-* (Bilski et al, 1979) whereas 
epanolol stimulated it only to 80 beats min”l (Data for 
clinical investigators on epanolol - ICI document), and 
therefore pindolol has more PAA than epanolol.
3.2 Subjects
Eight diabetic men (six taking insulin and two on oral 
hypoglocyaemic agents) aged 34 - 58 (mean 48.5) years and 
mean duration of diabetes 6 - 28 (mean 17) years with 
symptomatic autonomic neuropathy and markedly abnormal 
cardiovascular reflex function with involvement of both 
heart rate and blood pressure tests (table II) were 
studied. No subject had an abnormal 12-lead
electrocardiograph (ECG) or evidence of airways 
obstruction. The insulin or tablet regimes were not 
changed in any patient during the study.
3.3 Drugs used
The drugs used were epanolol (200 mg), atenolol (50 mg), 
pindolol (5 mg) and placebo, and the doses chosen were the 
'unit doses' used in clinical practice. At these doses
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each drug has a 24 hour duration of action in man (Aellig, 
1976; Harry, 1977; Floras et al, 1982; Pringle et al,
1986). The drugs were given as single oral doses in a 
double-blind randomised order with at least one week 
between dosing. Each patient received each drug and was 
therefore studied on four occasions.
3.4 Procedures
On each study day, the subjects were fitted with air 
ambulatory ECG tape recorder in the late morning, 
following which they were given their midday meal. 
Baseline measurements of resting heart rate, physiological 
tremor and blood glucose were made between 1 2 0 0 hours and 
1300 hours. The patients then received their single 
randomised dose of drug. Two and four hours after taking 
the tablets further measurements of heart rate, tremor and 
blood glucose were made. The patients were then allowed 
home to their usual daily activities while ambulatory 
monitoring was continued until lunchtime the following 
day.
3•5 Analysis
Missing data - there was a technical fault in part of the 
24 hour ECG recording of patient 1 after placebo, and 
this data has been omitted from analysis. The tremor 
recording 4 hours after atenolol on patient 8 was also 
technically unsatisfactory. The only glucose results
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obtained from patient 3 were at baseline and 2 hours after 
pindolol. No blood glucose results were obtained on 
patient 4 after atenolol. All other data obtained from 
all the subjects was used in the statistical analysis of 
the results.
The twenty four hour heart rate measurements were analysed 
over three periods: a first waking period of 1400 hours -
2300 hours; a second period of 2300 hours - 0800 hours,
*
when the subjects were assumed to be asleep; and 0800 
hours - 1300 hours the following morning.
3.6 RESULTS
Heart rate
Mean supine resting heart rates at baseline, and 2 and 4 
hours after each drug are shown in table III. Atenolol 
lowered heart rate significantly, whereas at 4 hours the 
heart rate after pindolol was higher than placebo, 
epanolol and atenolol. The heart rate following epanolol 
was similar to placebo but significantly higher than 
atenolol at 2 and 4 hours. The 24 hour mean heart rates 
are shown in table IV and figure 2. During the 'waking' 
hours (1400 - 2300 hours), the mean heart rates on 
epanolol and atenolol were less than placebo or pindolol 
with atenolol lower than epanolol. By contrast during 
the sleeping hours 2300 - 0800 hours the heart rate on
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pindolol was significantly higher than placebo, epanolol 
and atenolol, while the heart rate on atenolol was lower 
than on epanolol or placebo.
Physiological tremor
There were no significant changes seen in baseline 
physiological tremor over the four different study days 
thus showing that the tremor measurements were 
reproducible (table V, figure 3). At 4 hours post dose 
pindolol produced a significant increase in physiological 
tremor when compared with placebo, epanolol and atenolol. 
There were no differences between the tremor measurements 
on placebo, epanolol or atenolol (table V, figure 4).
Plasma glucose
Plasma glucose did not change significantly during the 4 
hour study period after placebo, epanolol or atenolol 
(table VI, figure 5). However, there was a rise after 
pindolol, which was significantly different from both 
epanolol and atenolol.
3.7 DISCUSSION
In this study, despite looking at a group of diabetics in 
whom there was clear evidence of both cardiac 
parasymapthetic and sympathetic dysfunction, no direct 
stimulating effects of B-adrenoreceptor blocking drugs
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with PAA were shown. However, relative changes in heart 
rate emerged which were more marked during sleep, and 
which could be considered to be dependent upon the 
different degrees of PAA in the drug used. If there had 
been complete absence of any sympathetic neural influence, 
as in the animal model, no drop in heart rate after 
atenolol would have been observed, and an increased heart 
rate after the drugs with partial agonism would have been 
seen, most marked on pindolol. From this evidence it 
might be inferred that complete sympathetic denervation 
was not present in these diabetics with severe autonomic 
neuropathy. These results contrast with those reported 
by Man in't Veld, Boomsa & Schalekamp (1982), who studied 
four patients with autonomic failure (two with amyloidosis 
and two with idiopathic orthostatic hypotension) after 
treatment with pindolol, both acutely by intravenous 
injection and chronically by oral administration. A rise 
in heart rate was demonstrated on both occasions. It 
seems likely that sympathetic denervation in these 
subjects was more complete than in the diabetics. 
Although my diabetics were severely affected, with grossly 
abnormal tests of cardiovascular reflex function, it is 
apparent that complete denervation was not present in 
them. It is interesting to speculate on whether or not 
it occurs in the later stages of the disease, when renal 
insufficiency intervenes (Ewing et al, 1980), or whether 
'complete' denervation occurs at all in the disease. It
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would also be useful to know whether heart rate falls in 
PAF subjects after dosing with atenolol. I am not aware 
of any literature on this subject.
The diurnal variation in heart rate in these diabetics was 
affected by the B-adrenoceptor blocking agents used in 
this study in proportion to the amount of partial agonism 
present. . The resting supine heart rate fell during the 4 
hours after dosage even on placebo, reflecting the normal 
afternoon heart rate pattern, and both epanolol and 
atenolol lowered the heart rate significantly more than 
pindolol, with atenolol producing the lowest heart rate. 
Pindolol, by contrast, lowered heart rate significantly 
less and at 4 hours after dosing the heart rate was 
significantly higher than on placebo. This pattern of 
heart rate change was also reflected in the 24 hour ECG 
tape recording. At night on pindolol, the drug in this 
study with most PAA, the heart rate was significantly 
higher than on placebo. On epanolol, which has less PAA 
than pindolol, the heart rate was similar to that on 
placebo, whilst after atenolol, with no PAA, the heart 
rate was significantly lower.
I have assumed that the heart rate changes after dosing 
with these drugs are mediated through cardiac Bi- 
adrenoceptors. Epanolol and atenolol are Bi-selective at 
the doses used and would appear to affect heart rate by
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this means. It could, however, be argued, from animal 
experiments, that pindolol, as well as acting on Bi~ 
adrenoceptors, might also be directly stimulating cardiac 
B2 -adrenoceptors to effect a relative increase in heart 
rate (Clark, Menninger & Bertholet, 1982). As yet there 
is no convincing support for this contention in man, 
although there is suggestive evidence that B2 - 
adrenoceptors may be present in the atria (Brown, MacLeod 
& Shand, 1983;, Brodde et al, 1983). Irrespective of the 
mechanism of the stimulant effect of pindolol it is clear 
that the heart rate results are consistent with epanolol 
and pindolol possessing partial agonism with respect to 
heart rate and that pindolol appears to have a greater 
effect on heart rate than epanolol.
The changes in physiological tremor produced by B- 
adrenoceptor blocking or stimulating agents can be used as 
a model of B2 -adrenoceptor activity. B2 -adrenoceptor 
agonists such as isoprenaline increase tremor, and 
differences between B^-selective and non-selective B- 
adrenoceptor blocking drugs can be detected in man (Arnold 
& McDevitt, 1983). As epanolol and atenolol are both 
selective Bi-adrenoceptor blocking drugs at this dosage, 
it was not surprising that physiological tremor was 
unchanged after these drugs. By contrast there was a 
significant increase in tremor values after the non- 
cardioselective drug pindolol which is known to have PAA.
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The effect of pindolol on tremor has not been previously 
demonstrated. These observations suggest that of the 
drugs studied, only pindolol has B2 ~adrenoceptor 
stimulating properties.
The surprising finding that pindolol, in contrast to the 
two cardioselective B-adrenoreceptor blockers, increased 
blood glucose values also suggests that B2 ~adrenoreceptors 
are stimulated by this drug. Isoprenaline (a B^- and 8 2 - 
adrenoceptor agonist), when given intravenously to man, 
increased blood glucose which was reduced by ICI 118,551 
(a B2 -selective antagonist) and not by atenolol (Arnold et 
al, 1985). This suggests that sympathomimetic amine- 
induced increases in glucose are due to stimulation of B2 - 
adrenoceptors probably promoting glycogenolysis in the 
liver (Weiner & Taylor, 1985; Rizza et al, 1980). The 
rise in glucose after pindolol in this study could 
therefore be explained by stimulation of B2 -adrenoceptors. 
This effect is probably mediated by denervation 
supersensitivity as DAN +ve patients also exhibit enhanced 
metabolic responses to catecholamines compared to normals 
and DAN -ve patients (Hilsted et al, 1987).
The results presented in this study clearly demonstrate 
that epanolol and pindolol show evidence of partial 
agonisra with their effects on heart rate. . By contrast, 
stimulation of tremor and blood glucose were seen only
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with pindolol. Pindolol thus appears to have PAA. at both 
Bi~ and B2 -adrenoceptors/ at least in the doses used in 
this study. Similar results might be seen in normal 
subjects and indeed some preliminary evidence (McCaffrey, 
Riddell & Shanks, 1986) supports this view. Despite the 
limitations of this study therefore, using diabetics with 
severe autonomic neuropathy as a model of denervation, 
changes in both Bi~ and B2 -adrenoceptor function have been 
observed which probably reflect the amount and selectivity 
of partial agonist activity in the drugs used.
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Age
(yrs)
Duration
(yrs)
Valsalva
ratio
30; 15 
ratio
Heart rate 
variation 
(beats ain“^)
Systoli c 
BP 
fall on 
standing 
(aaHg)
Diastoli c 
BP
rise during 
sustained 
handgrip 
(aaHg)
Autonoai c 
'score1
1 34 17 1.04 0.97 5 78 26 8
2 51 28 1.00 1.00 3 50 28 8
3 51 18 1.01 1.03 2 26 26 6
4 52 22 1.06 1.00 1 22 14 8
5 51 11 1.41 1.00 8 30 21 6
6 58 12 1.07 0.97 17 70 14 7
7 50 6 1.80 0.93 3 36 15 7
00 24 1.14 0.97 0 26 19 7
NoraaI values > 1.21 > 1.04 > 15 < 10 > 16
(Chapter 3)
AGE, DURATION OF DIABETES AND CARDIOVASCULAR REFLEX TEST RESULTS 
IN EIGHT DIABETICS STUDIED
TABLE II
PLACEBO
EPANOLOL
ATENOLOL
PINDOLOL
PflgeXlns
83.5 ± 4.8
83.3 ± 4.1
84.6 i 3.6
84.0 i 3.6
2 J m r.g.
80.0 t 3.8
76.4 ± 3.9 
68.8 ± 2.2
80.0 i 2.4
SIGNIFICANCE VALUES
2 hours
placebo vs epanolol 
placebo vs atenolol 
placebo vs pindolol 
epanolol vs atenolol 
epanolol vs pindolol 
atenolol vs pindolol
NS
p < 0 . 0 1
NS
p < 0.05 
NS
p < 0 . 0 0 1
4 hours
77.0 i 3.3
74.4 ± 3.1
67.5 ± 2.2 
80.9 ± 2.6
4 hours 
NS
p < 0 . 0 0 1
p < 0.05
p < 0 . 0 1  
p < 0 . 0 1  
p < 0 . 0 0 1
(Chapter 3)
GROUP MEAN RESTING SUPINE HEART RATES (beats rain”*1) AT 
BASELINE/ TWO AND FOUR HOURS AFTER TAKING EACH OF 
THE DRUGS OR PLACEBO (MEAN ± SEN) (n = 8 )
TABLE III
14.00 - 23.00 h 23.00 - 08.00 h 08.00 - 13.00 h
PLACEBO 89.0 ± 1.3 76.6 ± 1.2 (n = 7) 91.4 ± 1.6 (n = 7)
EPANOLOL 81.5 ± 1.0 76.5 ± 0.9 86.0 * 1.2
ATENOLOL 72.9 ± 0.8 68.0 ± 0.9 78.1 ± 1.2
PINDOLOL 85.8 ± 0.9 84.4 ± 1.4 90.1 ± 1.5
SIGNIFICANCE VALUES 
14.00 - 23.00 h 23.00 - 08.00 h 08.00 - 13.00 h
placebo vs epanolol p < 0.05 NS p < 0.05
placebo vs atenolol p < 0.001 p < 0.01 p < 0.001
placebo vs pindolol NS p < 0.05 NS
epanolol vs atenolol p < 0.05 p < 0.05 NS
epanolol vs pindolol p < 0.05 p < 0.01 NS
atenolol vs pindolol p < 0.001 p < 0.001 p < 0.01
©
(Chapter 3)
GROUP MEAN HEART RATES (beats nin~1) DURING THE 24 HOUR ECG RECORDINGS 
AFTER TAKING EACH OF THE DRUGS OR PLACEBO (MEAN ± SEM)
(n = 8 except where indicated)
TABLE IV
Baseline 2 hours 4 hours
PLACEBO 418.7 ±14.8 409.0 ± 16.3 395.7 ±14.8
EPANOLOL 419.8 ± 10.3 406.0 ± 16.2 402.0 ±16.4
ATENOLOL 418.6 ± 13.7 402.9 ± 12.9 394.0 ± 13.8 (n
PINDOLOL 417.1 ± 16.1 422.6 ±17.8 425.8 ± 17.6
= 7)
placebo vs epanolol 
placebo vs atenolol 
placebo vs pindolol 
epanolol vs atenolol 
epanolol vs pindolol 
atenolol vs pindolol
SIGNIFICANCE VALUES
2 hours 4 hours
NS NS
NS NS
NS p < 0.01
NS NS
NS p < 0.05
NS p < 0.05
(Chapter 3)
GROUP MEAN TREMOR MEASUREMENTS (LOG TREMOR READINGS SUMMED 
OVER FREQUENCY) AT BASELINE, TWO AND FOUR HOURS AFTER 
TAKING EACH OF THE DRUGS OR PLACEBO (MEAN ± SEM)
(n = 8 except where indicated)
TABLE V
Baseline 2 hours 4 hours
PLACEBO 11.1 ± 1.5 (n=7) 11.6 ± 1.9 (n=7) . 11.6 ± 1.3
iicV
EPANOLOL 14.4 ± 3.5 (n=7) 14.6 ± 2.5 (n=7) 13.3 ± 2.5 (n=7)
ATENOLOL 10.1 ± 2.7 (n=6) 11.2 i 2.1 (n=6) 10.5 ± 1.7
oiic
PINDOLOL 11.2 ± 2.3 (n=8) 15.1 ± 2.1 (n=8) 16.3 ± 2.3
I'­llc
placebo vs epanolol 
placebo vs atenolol 
placebo vs pindolol 
epanolol vs atenolol 
epanolol vs pindolol 
atenolol vs pindolol
SIGNIFICANCE VALUES
2 hours 
NS 
NS
p < 0.05 
NS
p < 0.05
p < 0.01
4 hours 
NS 
NS
NS (p=0.059) 
NS
p < 0.01 
p < 0.01
(Chapter 3)
GROUP MEAN PLASMA GLUCOSE VALUES (mmol I"1) AT BASELINE, TWO AND FOUR 
HOURS AFTER TAKING EACH OF THE DRUGS OR PLACEBO (MEAN ± SEM) 
(numbers of subjects are indicated in brackets)
TABLE VI
ME
AN
 
HO
UR
LY
 
HE
AR
T 
RA
TE
 
(b
aa
ts
m
irH
)
100-1
9 0 -
80-
'Ck>rr*'D‘ «
75-
70-
65-
12 14 18 18 20 22 24 2 4 6 8 10 12
TIME (hours)
Group mean hourly heart rate during ambulatory monitoring 
over the 24 h after dosing with placebo (o), epanolol (•)/ 
atenolol (□) and pindolol (■).
Figure 2
f2
8
I i 2
» 1
IIii
150-
14-5-
12-5-
10|£ —1-
10
—T“ 
12
“r~ 
14
r-
16
—r~ 
18
t -
20 22
—i-------r—
24 26
— i—  
28
—i
30
FREQUENCY (HZ)
Group mean log tremor measurements at each frequency 
(range 0-30 Hz) at baseline before dosing with placebo 
(o), epanolol (•), atenolol (□) and pindolol'(■).
Figure 3
0  2 4 6 8 1 0  12 14 16 1 8 2 0 2 2  24 2 6 2 8
FREQUENCY (HZ)
Group mean log tremor measurements at each frequency 
(range 0 - 3 0  Hz) 4 h after dosing w i t h  placebo (o), 
epanolol (•), atenolol (□) and pindolol (■).
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2 and 4 h after dosing with placebo (o), epanolol (•)/ 
atenolol (□) and pindolol (■).
Figure 5
[APTER 4
VASOPRESSIN SECRETION FOLLOWING OSMOTIC STIMULATION 
KITH HYPERTONIC SALINE IN DIABETICS KITH AND 
WITHOUT AUTONOMIC NEUROPATHY
4.1. SUBJECTS
Eleven male insulin-dependent diabetics were studied: 
five without (DAN -ve) and six with (DAN +ve) 
cardiovascular reflex test evidence of autonomic 
neuropathy. Within the two groups there was a similar 
distribution of ages and duration of diabetes (table VII). 
All six DAN +ve subjects had one or more symptoms 
suggestive of autonomic neuropathy together with clinical 
evidence of somatic nerve involvement. Proteinuria 
(albustix +ve) was present in 1 DAN -ve and 1 DAN +ve 
patients, while retinopathy was present in 2 DAN -ve (1 
background, 1 proliferative) and all 6 DAN +ve patients (1 
background, 5 proliferative) patients. Plasma creatinine 
values ranged from 86 to 123 (mean DAN -ve 99, DAN +ve 
104) umol 1"! in the eleven subjects in whom it was 
measured.
The studies were conducted in a quiet room under standard 
conditions. In addition to the diabetics, five normal
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volunteers aged 35 - 48 (mean 43) years took part, using 
an identical protocol. The subjects fasted overnight and 
(the diabetics) delayed their usual morning insulin dose 
until after the study was completed. They were asked to 
abstain from alcohol, caffeine and smoking for at least 
twelve hours prior to the study, which commenced at around 
0900 hours. No subjects were receiving any drugs other 
than insulin None complained of nausea (a powerful 
stimulus to AVP secretion) during the studies.
4.2 Protocol
Each subject lay supine while an intravenous cannula was 
inserted into each antecubital fossa: the left for
sampling and the right for infusion. After thirty 
minutes rest, an infusion of 5% saline was given at a rate 
of 0.05 mg kg body weight”  ^ min“l over the next 120 
minutes. Blood was withdrawn at -10, -5, 0, +30, +60, 
+90 and +120 minutes for estimation of haematocrit, plasma 
osmolality, sodium, glucose and AVP. Heart rate and 
blood pressure were measured at -10, -5 and 0 and then at 
10 minute intervals throughout the study. Further 
details of analysis are given in chapter 2.
4.3 RESULTS
There were no significant differences in baseline values 
between the groups with respect to plasma osmolality,
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sodium, plasma AVP arid haematocrit. Plasma glucose was 
similarly raised in the two diabetic groups (table VUIb). 
Baseline blood pressure and heart rate were slightly 
elevated in the DAN +ve group (figure 6).
During the 120 minute 5% saline infusion, plasma 
osmolality and sodium rose appropriately in parallel, with 
no significant differences in response between the three 
groups (table Villa, figure 7). An elevation of plasma 
AVP accompanied the rises in osmolality and sodium, so 
that there was a very close linear relationship between 
both plasma osmolality and AVP, and plasma sodium and AVP, 
in each of the groups (table IX) . There were no 
significant differences in the plasma AVP area under the 
curve responses between the three groups.
Haematocrit fell slightly in all three groups, while 
plasma glucose remained unchanged (table VUIb, figure 7). 
There were no significant differences in the mean blood 
pressure and heart rate responses between the three 
groups, although blood pressure rose most in the DAN +ve 
group. One DAN +ve subject (no 8) had a 30 mmHg rise in 
systolic blood pressure at 110 minutes, and for safety 
reasons the study was stopped at this point. Samples 
taken then were considered equivalent to 120 minutes.
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4.4 DISCUSSION
This work demonstrates that osmotic release of AVP after 
infusion of hypertonic saline appears to be intact in 
diabetics both with and without autonomic neuropathy. 
Similar rises in plasma osmolality after five per cent 
saline infusion produced appropriate rises in plasma AVP 
in the diabetic and normal subjects, with a very close 
correlation between plasma osmolality and AVP, and plasma 
sodium and AVP during the infusion period. This
relationship has been well recognised previously (Zerbe, 
Vinicor & Robertson, 1985; Vokes et al, 1987; Thompson et 
al, 1988), and there were no significant differences in 
AVP response between the three groups.
Diabetics with and without autonomic neuropathy therefore 
appear to respond in a normal fashion to an osmotic 
stimulus. This effectively excludes any significant
abnormality of hypothalamic or posterior pituitary 
function and demonstrates the integrity of the neural 
pathways involved in osmotic control of AVP. Other
groups with abnormalities of autonomic function have also 
been shown to respond normally, for example, patients with 
primary autonomic failure (Williams, Lightman & Bannister, 
1985) and subjects with spinal cord transection (Poole et 
al, 1987).
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Although one of the DAN +ve subjects had a marked 
hypertensive response to hypertonic saline infusion, no 
significant group changes were observed in the diabetics. 
This is in contrast to those results found in patients 
with PAF (Williams, Lightman & Bannister, 1985) and in 
tetraplegics (Poole et al, 1987), in both of whom 
hypertonic saline produced a significant pressor response, 
which at least in part seems to be secondary to increased 
sensitivity to AVP at vascular level. Chapter 6 will 
address this issue further in a diabetic group.
108
o
•r
■ V O
o L. r~
c o 1
o o O
4-> tO w
3
<
1 CL
1 CO O)
C
1 o •r
1 ’r C_ y"^
I —» 3 Q. 05
1 o •o •F“ X
1 4-» <_ E
1 M 41 05 e
1 ID <0
1 -r •r-
1 O C-
1 Q.
1 CO
c 051 o o C y-v
1 'r •r 05I w XI X1 o C E
1 +» to « E
1 0) 4-» N_y
1 X 0)
1 CO
1 4> «—
1 4-* C 1
1 ID o C1 C_ •r •f
E
1 4-* a1 C_ •r <01 to C_ +->
1 4) a a
1 X > 4)
i in o
1 r- •r-
1 * ■ 4->
1 O a
i ro
i to
i >
i —* o
1 to ■r—1 to 4->1 a1 to l.
1 >
« PN
c r-
i to 'P- 1
1 E c
1 <0 ■r-1 to 4-»I —' a O
1 CL 4) Eu 3
o w
1 «J
1 *f“ /■"»
1 L X
1 3 •r
1 C 4->
1 *r <0
1 €> 3
1 +-> A
1 O1 c. «
i a .
1 X ■o
1 JC c 4>
1 4-> 3 >
i a 01 O ■F—
i a. 3 c_ 4-»
1 o 4-» 05 «J
1 c « .X 73
1 'r 4-> O 3
1 +-> to a X
1 4) J0 4)
1 X ii II
CO LUw
1 C <4
1 o 4)
1 T" 4->
1 4-* 41 to
i a O JO u
1 c. a X
1 3 *•“ w
i a TJ
/■>
1 41 to
1 05 u
1 < X
1 4->
1 c
1 4)
1 'r
1 4->
1 a o
1 CL z
CO ootu
IN 
TH
E 
DI
AB
ET
IC
S 
UN
D
ER
GO
I
NG
 
5%
 
SA
LI
NE
 
I
N
F
U
S
I
O
N
Baseline
TIME (nin)
30 60 90 120 Area under 
curve 0-120 nin 
(Arbitrary units)
Di fference 
f ron 
baseline
PLASMA OSMOLALITY 
(nosn kg"^)
DAN +ve
(n a 6)
291.7
(4.8)
295.3
(5.0)
299.3
(5.4)
302.2
(4.4)
306.0
(4.8)
870
(121)
p < 0.001
DAN -ve 
(n = 5)
286.4
(6.1)
289.2
(6.0)
294.8
(4.3)
298.4
(3.5)
302.0
(4.0)
930
(238)
p < 0.001
Nornals 
(n = 5)
285.0
(3.4)
287.6
(4.0)
290.6
(4.5)
293.4
(4.8)
295.0
(5.0)
648
(198)
p < 0.00
F value 2.90 (NS) 3.18 (NS)
PLASMA SODIUM 
(nmol l"^)
DAN +ve 136.3
(3.2)
138.2
(3.5)
140.3
(3.6)
142.7
(3.1)
144.3
(2.6)
485
(73)
p < 0.001
DAN -ve 138.0
(1.6)
139.6
(1.5)
140.6
(1.3)
143.2
(2.0)
145.0
(2.0)
387
(63)
p < 0.001
Normals 139.0
(1.2)
140.4
(2.7)
143.2
(1.8)
144.2
(1.9)
145.8
(1.9)
426
(118)
p < 0.005
F value 1.94 (NS) 1.78 (NS)
PLASMA AVP 
(pmol l"^)
DAN +ve 1.26
(0.78)
1.63
(0.96)
2.21
(1.38)
3.76
(2.38)
5.24
(3.24)
174
(109)
p < 0.02
DAN -ve 1.80
(0.64)
2.78*
(1.23)
3.38
(2.04)
3.80
(1.5)
5.32
(2.99)
168
(225)
NS
Normals 0.94
(0.91)
1.48
(0.85)
2.33
(0.79)
2.76
(0.59)
5.02*
(2.03)
155
(50)
p < 0.005
F value 1.54 (NS) 0.02 (NS)
* n = 4
(Chapter 4)
GROUP MEAN (SO) BIOCHEMICAL AND OSMOLALITY RESPONSES DURING 120 MINUTES OF 
5% SALINE INFUSION IN DIABETICS WITH (DAN + VE), DIABETICS WITHOUT
(DAN -ve) AUTONOMIC NEUROPATHY, AND NORMAL SUBJECTS TABLE Villa
TABLE Villa
TIME (min)
Baseline 30 60 90 120 Area under 
curve 0-120 min 
(Arbitrary units)
Di fferen 
from 
baselin
HAEMATOCRIT (%)
DAN +ve 40.5
(2.9)
40.0
(3.2)
39.8
(3.7)
39.0
(3.6)
38.7
(3.4)
-107
(70)
p < 0.05
DAN -ve 41.2
(2.4)
40.6
(2.9)
39.8
(3.4)
40.0
(2.7)
39.6
(3.0)
-120
(78)
p < 0.02
Normals 41.4
(2.4)
40.2
(2.6)
39.4
(2.4)
39.0
(2.5)
38.2
(2.8)
-216
(55)
p < 0.001
F value 0.18 (NS) 3.93 (p<0.05)
PLASMA GLUCOSE 
(mmol l”^)
DAN +ve 10.3
(4.8)
10.3
(4.6)
10.4
(4.9)
10.8
(5.7)
10.8
(5.8)
27
(67)
NS
DAN -ve 10.1
(5.2)
9.9
(4.9)
10.4
(4.6)
10.6
(4.3)
10.8
(4.3)
31
(80)
NS
Normals 5.5
(0.7)
5.6
(0.6)
5.6
(0.6)
5.3
(0.6)
5.3
(0.7)
3
(38)
NS
F value 2.20 (NS) 0.28 (NS)
(Chapter 4)
GROUP MEAN (SD) BIOCHEMICAL AND OSMOLALITY RESPONSES DURING 120 MINUTES OF 
5% SALINE INFUSION IN DIABETICS WITH (DAN +ve), DIABETICS WITHOUT 
(DAN -ve) AUTONOMIC NEUROPATHY, AND NORMAL SUBJECTS
TABLE V UIb
Correlation 
Coeffi ci ent
Slope x intercept
PLASMA OSHOLALITY 
vs
PLASMA AVP
DAN +ve 
(n = 6)
DAN -ve 
(n = 5)
Normals 
(n = 5)
F value
0.84
(0.10)
0.91
(0.13)
0.89
(0.08)
0.51 (NS)
0.28
(0.18)
0.22
(0.15)
0.33
(0.10)
0.62 (NS)
287
(8)
272
(9)
283
(2)
6.1 (p<0.05)
PLASMA SODIUM 
vs
PLASMA AVP 
DAN +ve
DAN -ve
Norma Is
F value
0.84
(0.10)
0.91
(0.13)
0.89
(0.08)
0.62 (NS)
0.50
(0.38)
0.53
(0.30)
0.45
(0.11)
0.08 (NS)
133 
(5)
134 
(2)
137
(1)
1.66 (NS)
(Chapter 4)
LINEAR REGRESSION RELATIONSHIPS BETWEEN PLASMA OSMOLALITY, 
SODIUM, AND AVP DURING 5% SALINE INFUSION IN DIABETICS WITH 
(DAN +ve) AND WITHOUT (DAN -ve) AUTONOMIC NEUROPATHY 
AND NORMAL SUBJECTS (MEAN (SD))
TABLE IX
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Mean blood pressure and heart rate during 120 minutes of
5% saline infusion in six diabetics with (o o), five
diabetics without (• •) autonomic neuropathy/ and five
normal subjects ( ■ ---■ ).
Figure 6
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Mean biochemical and osmolality responses during 120 
minutes of 5% saline infusion in six diabetics with
(o o), five diabetics without (•— -•) autonomic
neuropathy and five normal subjects ( ■ ---■ ).
Figure 7
CHAPTER 5
VASOPRESSIN SECRETION IN RESPONSE TO HEAD-UP TILT IN 
DIABETICS WITH AND WITHOUT AUTONOMIC NEUROPATHY
5.1 SUBJECTS
Thirteen male insulin-dependent diabetics were studied: 
six without (DAN -ve) and seven with (DAN +ve) 
cardiovascular reflex test evidence of autonomic 
neuropathy. The two groups were similar in age and 
duration of diabetes (table X). All seven DAN +ve 
patients had symptoms of autonomic neuropathy and clinical 
evidence of somatic nerve involvement. Proteinuria 
(albustix +ve) was present in 1 DAN -ve and 1 DAN +ve 
patient, while retinopathy was present in 1 DAN -ve 
(proliferative) and all seven DAN +ve (2 background, 1 
exudative, 4 proliferative) patients. Plasma creatinine 
values ranged from 81 - 123 (mean DAN -ve 98.6 + 17, n = 
5, DAN +ve 97.5 ± 10, n = 7) umol 1”! in the subjects in 
whom it was measured.
In addition, six normal volunteers aged 35 - 48 (mean 42) 
years underwent tilt.
The same precautions regarding tobacco, caffeine and 
alcohol were observed as in chapter 4. Insulin was
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withheld until after the study was completed.
5.2 Protocol
Each subject lay supine on a tilt table with a footrest, 
while an intravenous cannula was inserted into a left 
antecubital vein. After 30 minutes rest, the subject was 
tilted at 45° head-up over 15 seconds, and remained in 
this position for 120 minutes. Blood was withdrawn at 
-10, -5, 0, +30, +60, +90 and +120 minutes for
haematocrit, plasma osmolality, sodium, glucose, AVP, 
plasma renin activity (PRA), aldosterone, and 
catecholamines (noradrenaline and adrenaline). Heart 
rate and blood pressure measurements were made at -10, -5 
and 0 and then at 10 minute intervals throughout the 
study.
5.3 RESULTS
Baseline values for plasma sodium, AVP, adrenaline and 
aldosterone were not significantly different between the 
three groups (tables XIa,b, XIIa,b). Osmolality was 
higher and noradrenaline lower in the DAN +ve group and 
PRA higher in the normal group. Baseline plasma glucose 
values were elevated in both diabetic groups, but there 
were no significant differences in baseline glucose values 
between the two diabetic groups. Blood pressure and 
heart rate at baseline were higher in the DAN +ve group
110
(figure 8).
Immediately after tilting, blood pressure fell 
significantly and continued to fall throughout the 120 
minute period in the DAN +ve group, (systolic blood 
pressure drop shown in figure 9), whereas there was a 
slight, but non significant rise in the DAN -ve and normal 
groups. Heart rate rose slightly but significantly in 
all three groups (figure 8).
Biochemical variables are shown in tables XIa,b and 
XIIa,b. Plasma osmolality and sodium altered slightly 
during the tilt study, while haematocrit rose similarly 
and significantly in all three groups. After tilt, small 
rises in plasma AVP, which were significant only in the 
normal group were seen. There were no significant 
differences in AVP responses between the three groups 
(figure 10). During the 120 minute tilt, plasma glucose 
increased in both diabetic groups, whereas the normal 
group showed no change. PRA and plasma aldosterone rose 
appropriately during the study in all groups, whereas 
plasma noradrenaline and adrenaline showed little change.
5.4 DISCUSSION
There was no difference in AVP response • during tilt 
between diabetic and normal subjects. However, the
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failure of a significant AVP rise in the autonomic 
neuropathy group, despite a major hypotensive stimulus 
suggests that in this group there is, in fact, a defect in 
cardiovascular control of AVP release. The secretion of 
AVP in response to cardiovascular stimuli is dependent on 
intact intrathoracic receptors, afferent fibres in the 
IXth and Xth nerves and brain stem pathways to the 
hypothalamus. Subjects with progressive autonomic
failure, with defective catecholamine pathways in the 
brain stem, have a loss of AVP response to head-up tilt in 
spite of the added stimulus of postural hypotension 
(Puritz et al, 1983). This contrasts with the amplified 
AVP response found in patients with selective loss of 
sympathetic pathways due to cervical cord transection 
(Sved et al, 1985; Poole et al, 1987). These results in 
diabetics with autonomic neuropathy reveal a subnormal AVP 
response to the postural fall in blood pressure that 
occurred on tilting. In a previous study looking at AVP 
levels before and after standing for two hours, four of 
nine diabetics with autonomic neuropathy had diminished 
AVP responses, but only two had postural hypotension 
(Cignarelli et al, 1986). In another study, abnormal AVP 
responses were found to volume depletion in diabetics with 
abnormal cardiovascular heart rate responses (Grimaldi et 
al, 1985).
Considerable evidence now exists to suggest that AVP
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release after head-up tilt serves as an index of the 
integrity of afferent cardiovascular pathways (Puritz et 
al, 1983; Poole et al, 1987; Zerbe et al, 1983). This 
study suggests that diabetics with autonomic neuropathy, 
like subjects with PAF, also have defective cardiovascular 
release of AVP. It might be argued that an alternative 
explanation of the low AVP response in the DAN +ve group 
was their higher blood glucose (see 1.3.4). In this 
study, while the mean glucose values were higher in the 
DAN +ve group, they were not significantly different from 
the DAN -ve group.
Similarly, although the DAN +ve group were slightly older 
(mean 45 years) than the DAN -ves (mean 40 years) or 
normals (mean 42 years), the evidence for an age-related 
effect producing the low AVP response in these patients is 
poor, considering that this effect is not viewed as a 
general feature of ageing (Rowe et al, 1982).
Despite lower baseline plasma renin activity, the diabetic 
autonomic neuropathy group showed a significant rise after 
tilt. This is in contrast to previous studies showing low 
renin production in diabetic autonomic neuropathy 
(Campbell et al, 1976; Christlieb, Munichoodappa & 
Braaten, 1974), but is in keeping with more recent work 
(Hilsted et al, 1981a; Winocour, Dahr & Anderson, 1986).
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The presence of nephropathy and possible disruption of the 
juxta-glomerular apparatus in end-stage diabetes, may be 
more likely to be responsible for a low renin response.
Plasma noradrenaline levels were lower in the autonomic 
neuropathy group at baseline. Previous reports have
shown inconsistent patterns of resting supine 
noradrenaline (Cryer et al, 1978; Hilsted et al, 1981b; 
Ewing et al, 1986; Dejgard, Hilsted & Christensen, 1986; 
Matthews et al, 1987).
In conclusion, this study shows that diabetics with 
cardiovascular reflex evidence of autonomic neuropathy 
show a defective AVP response to the cardiovascular 
stimulus of head-up tilt. Such a pattern is also seen in 
patients with progressive autonomic failure but contrasts 
with the response in subjects with selective efferent 
sympathetic loss secondary to spinal cord transection. 
This suggests that afferent cardiovascular pathways are 
also damaged in these diabetic subjects.
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Baseline
TIME (min)
30 60 90 120 Area under Difference
curve 0-120 Bin from
(Arbitrary units) baseline
PLASMA OSMOLALITY 
(mosm kg~1)
DAN +ve 
(n = 7)
DAN -ve 
(n = 6)
Normals 
(n = 6)
F value
PLASMA SODIUM 
(mmol I”1)
DAN +ve
DAN -ve
Norma Is
F value
PLASMA AVP 
(pmol l"^)
DAN +ve
DAN -ve
Normals
F value
292.3 293.3
(3.7) (3.9)
283.0 283.2
(4.8) (5.2)
283.7 283.8
(2.0) (1.9)
13.20 (p<0.01)
293.9
(2.8)
283.3
(4.5)
284.0
(2.6)
294.3
(3.5)
283.0
(5.1)
284.7
(2.1)
295.0 
(3.2)
283.8
(5.1)
285.0 
(2.0)
137.8 137.6
(2.9) (2.9)
138.3 137.8
(1.7) (1.6)
139.2 139.0
(1.7) (1.9)
0.55 (NS)
137.0 
(3.3)
137.1
(1.9)
139.0
(1.9)
137.1
(3.1)
137.0
(1.4)
138.8
(1.8)
136.7 
(3.5)
137.2
(1.7)
138.7 
(2.0)
1.39 1.22
(1.17) (0.81)
1.58 1.48
(0.43) (0.41)
0.96 0.98
(1.16) (1.11)
0.60 (NS)
1.64
(1.14)
1.98
(1.13)
1.38
(1.30)
1.64
(1.34)
1.86
(0.47)
2.08
(1.89)
2.00
(1.16)
2.26
(1.00)
1.09
(0.70)
178
(144)
27
(198)
65
(93)
1.70 (NS)
-73
(78)
-107
(72)
-27
(74)
1.73 (NS)
19
(78)
28
(30)
48
(43)
0.46 (NS)
p < 0.02
NS
NS
p < 0.05
p < 0.02
NS
NS
NS
p < 0.05
(Chapter 5)
GROUP MEAN (SD) BIOCHEMICAL AND OSMOLALITY RESPONSES DURING 120 MINUTES OF HEAD-UP 
TILT TO 45° IN DIABETICS WITH (DAN +ve), DIABETICS WITHOUT (DAN -ve),
AND NORMAL SUBJECTS
TABLE XIa
Baseline
TIME (min)
30 60 90 120 Area under Difference
curve 0-120 min from
(Arbitrary units) baseline
HAEMATOCRIT (%)
DAN +ve 41.8 43.4 44.6 43.7 43.4 208 p < 0.02
(6.1) (7.8) (7.7) (7.6) (7.3) (170)
DAN -ve 40.8 41.8 41.8 42.7 42.3 137 p < 0.005
(3.0) (3.4) (3.5) (3.2) (3.1) (53)
Normals 41.0 41.8 42.5 43.7 43.8 192 p < 0.005
(2.0) (2.0) (1.9) (2.1) (2.3) (93)
F value 0.11 (NS) 0.60 (NS)
PLASMA GLUCOSE
(mmol l“1)
DAN +ve 14.9 15.4 15.9 16.4 17.0 122 p < 0.001
(7.5) (7.3) (7.5) (7.4) (7.0) (54)
DAN -ve 8.5 8.8 9.5 10.4 11.2 138 p < 0.02
(3.9) (3.8) (3.7) (3.8) (4.1) (88)
Normals 5.3 5.4 5.3 5.1 4.9 -12 NS
(0.7) (0.8) (0.7) (0.7) (0.6) (26)
F value 5.94 (p<0.05) 11.21 (p<0.01)
(Chapter 5)
GROUP MEAN (SD) BIOCHEMICAL AND OSMOLALITY RESPONSES DURING 120 MINUTES OF HEAD-UP 
TILT TO 45° IN DIABETICS WITH (DAN +ve), DIABETICS WITHOUT (DAN -ve),
AND NORMAL SUBJECTS
TABLE Xlb
TIME (min)
Baseline 30 60 90 120 Area under Difference
curve 0-120 min from
(Arbitrary units) baseline
PRA
(ng ml”^hr"^)
DAN +ve 0.44 1.31 1.85 1.85 2.08 123 P < 0.05
(0.21) (0.95) (1.54) (1.23) (1.65) (113)
DAN -ve 0.40 0.72 0.94 1.24 1.57 69 NS
(0.18) (0.50) (0.77) (1.20) (1.41) (85)
Normals 1.72 2.72 3.30 3.07 3.24 141 P < 0.05
(1.20) (0.90) (1.90) (1.40) (1.40) (107)
F value 7.43 (p<0.01) 0.80 (NS)
PLASMA ALDOSTERONE
(pg ml“1)
DAN +ve 111.1 125.7 152.6 177.1 179.7 4689 P < 0.02
(58.1) (79.2) (79.4) (81.8) (74.8) (3892)
DAN -ve 72.5 79.3 99.0 111.5 138.5 3160 NS
(41.2) (26.8) (48.0) (40.6) (45.3) (3343)
Normals 97.5 122.7 176.2 168.3 161.0 6192 NS
(37.0) (42.0) (71.0) (57.0) (73.0) (6512)
F value 1.10 (NS) 0.62 (NS)
(Chapter 5)
GROUP MEAN (SD) BIOCHEMICAL AND OSMOLALITY RESPONSES DURING 120 MINUTES OF 
HEAD-UP TILT TO 45° IN DIABETICS WITH (DAN +ve), DIABETICS WITHOUT 
(DAN -ve), AND NORMAL SUBJECTS
TABLE Xlla
TIME (min) 
Baseline 30 60 90 120 Area under Difference
curve 0-120 min from
(Arbitrary units) baseline
PLASMA NORADRENALINE 
(nmol l“1)
DAN +ve 0.83 0.96 0.98 0.97 0.88 657
(n = 7) (0.25) (0.34) (0.36) (0.35) (0.24) (532)
DAN -ve 1.48 1.59 1.65 1.66 1.51 723
(n = 6) (0.27) (0.38) (0.42) (0.36) (0.42) (1255)
Normals 1.36 1.49 1.41 1.36 1.39 186
(n = 6) (0.31) (0.27) (0.23) (0.31) (0.25) (380)
F value 10.17 (p<0.01) 0.81
PLASMA ADRENALINE
(nmol 1“^)
DAN +ve 0.16 0.19 0.19 0.15 0.14 80
(0.07) (0.05) (0.10) (0.07) (0.07) (209)
DAN -ve 0.22 0.25 0.26 0.23 0.20 84
(0.03) (0.07) (0.06) (0.07) (0.04) (250)
Norma Is 0.21 0.22 0.22 0.22 0.20 36
(0.06) (0.08) (0.06) (0.10) (0.06) (219)
F value 2.60 (NS) 0.09
(Chapter 5)
GROUP MEAN (SD) BIOCHEMICAL AND OSMOLALITY RESPONSES DURING 120 MINUTES OF 
HEAD-UP TILT TO 45° IN DIABETICS WITH (DAN +ve), DIABETICS WITHOUT 
(DAN -ve), AND NORMAL SUBJECTS
TABLE Xllb
MEAN
BLOOD 100-
PRESSURE
(mmHg)
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’'O
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i---- «— i-- i— i--- i------»—  i--- 1-- 1— i---- 1— i
0 30 60 90 120
TIME (MIN)
Mean blood pressure and heart rate during 120 minutes of
head-up tilt to 45° in seven diabetics with (o o), six
diabetics without (•-- •) autonomic neuropathy/ and six
normal subjects ( ■---■ ).
Figure 8
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Change in systolic blood pressure during 120 minutes of
head-up tilt to 45° in seven diabetics with (o o), six
diabetics without (•— •) autonomic neuropathy/ and six 
normal subjects ( ■-- ■ ).
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Mean biochemical and osmolality responses during 120 
minutes of head-up tilt to 45° in seven diabetics with
(o o), six diabetics without (•-- •)/ and six normal
subjects ( ■ ---■ ).
Figure 10
CHAPTER 6
THE PRESSOR EFFECT OF ARGININE VASOPRESSIN IN 
DIABETIC AUTONOMIC NEUROPATHY
6.1 SUBJECTS
Sixteen insulin-taking diabetic men were studied. They 
were divided into two groups: 8 DAN -ve and 8 DAN +ve,
assessed by cardiovascular reflex testing. [Details are 
given in table XIII]. All 8 DAN +ve subjects had one or 
more symptoms suggestive of autonomic neuropathy. 
Proteinuria (albustix +ve) was present in 2 DAN -ve and 1 
DAN +ve patients, while retinopathy was present in 3 DAN - 
ve (2 background, 1 proliferative) and 8 DAN +ve (2 
background, 6 proliferative) patients. The fasting and 
abstention requirements in chapters 4 and 5 were also 
observed.
Six normal male volunteers aged 26 - 57 (mean 37) years 
were studied at the Westminster Hospital, London, using a 
similar protocol.
6.2 Protocol
Each subject lay supine while intravenous cannulae were 
inserted into each antecubital fossa: the left for
sampling and the right for infusion. After 30 minutes
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rest, an infusion of AVP was started at 0.05 pmol min”1 kg 
body weight”1 and increased incrementally every 5 minutes 
to 0.2, 0.5, 1.0, 2.5 and 5 pmol min”1 kg”1 in the two 
diabetic groups. In the normal volunteer group the AVP 
infusion was started at 0.2 pmol min”1 kg"1 and increased 
every 5 minutes to 0.5, 1.0, 2.0 and 5 pmol min”1 kg”1. 
Heart rate (HR) and arterial blood pressure (BP) were
measured at -10, -5, and 0 minutes, and then during the
infusion at 2 minute intervals in the diabetic subjects
and at 5 minute intervals in the normal subjects. Blood 
was withdrawn every 5 minutes for estimation of plasma AVP 
and glucose concentrations.
6.3 RESULTS
Appropriate plasma AVP concentrations were achieved in all 
subjects at each incremental AVP infusion rate (figure
11). There were no significant differences in mean plasma 
AVP responses between the three groups over the infusion 
period (f = 0.6, NS). Marked facial pallor was seen in 
all subjects during the infusions.
Blood pressure and heart rate values at baseline did not 
differ significantly within each group between the -10, -5 
and 0 minute measurements. Baseline blood pressure was 
higher in the DAN +ve group. Group mean blood pressure 
(MBP) responses to AVP infusion are shown in figure 12,
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and systolic and diastolic blood pressure and heart rate 
responses in figure 13. There were no significant 
changes in the normal group or in the DAN -ve group. In 
the DAN +ve group there were mean rises of 11 mmHg in 
systolic blood pressure, and 10 mmHg in diastolic blood 
pressure by the 2.5 pmol min”* kg"* infusion rate. 
Because of the wide distribution of individual responses 
in .the diabetic groups, there were no significant 
differences between the groups in overall MBP responses 
during the infusion (AUC, normals, 4.9 ± 3.8 (SD), DAN -ve 
3.5 + 7.4, DAN +ve 9.7 ± 5.9, f = 2.3, NS).
Examination of the individual responses, however, showed 
that 6 of the 8 DAN +ve subjects (numbers 9, 10, 11, 14, 
15, 16) and 2 of the 8 DAN -ve subjects (numbers 5 and 7) 
had overall blood pressure responses greater than any of 
the normal subjects and clearly different from the other 
diabetic subjects (figure 14). One of the 2 DAN -ve 
subjects (number 7), with a marked pressor response to AVP 
infusion was found subsequently to have a low 24 hour 
heart rate variation count (Ewing et al, 1984), suggesting 
early autonomic involvement. Maximum mean blood pressure 
rises in these subjects were 13, 21, 11, 14, 17 and 12
mmHg (DAN +ve) and 22 and 19 mmHg (DAN -ve). This
contrasts with maximum mean blood pressure rises of 2 and 
8 mmHg (DAN +ve numbers 12 and 13) and 8, 6,,0, 1, 3 and 0 
mmHg (DAN -ve numbers 1, 2, 3, 4, 6 and 8). Additionally
117
in all but one of the subjects with pressor responses, the 
greatest blood pressure rises occurred at intermediate AVP 
infusion levels, with an attenuated blood pressure 
response at the 5 pmol rain“l kg~* infusion rate.
Although there was a faster baseline heart rate in the DAN 
+ve group (as might be expected), there were no 
significant differences in the heart rate responses 
between the groups. Heart rate fell on average 4-8 beats 
per minute in all three groups during the infusion period, 
but rose again at the highest AVP infusion rate (figures 
13 and 14). There were no significant differences 
between the diabetic groups in plasma glucose, either at 
baseline or during the study.
6.4 DISCUSSION
Arginine vasopressin is a very powerful vasoconstrictor 
which in experimental animals has been shown to exert 
differential effects on different vascular beds (Monos, 
Cox & Peterson, 1978; Liard et al, 1982). In normal man 
infusion of small doses of AVP results in a small rise in 
systemic vascular resistance (Ebert et al, 1986), but 
higher doses have little, or only transient pressor 
effects (Williams et al, 1986; Graybiel and Glendy, 1941; 
Simpson et al, 1986). Increased pressor sensitivity to 
exogenous AVP has, however, been reported in patients with
118
abnormalities of the autonomic nervous system, including 
patients with progressive autonomic failure (Wagner & 
Braunwald, 1956; Mohring et al, 1980; Williams et al,
1986), and tetraplegics (Poole et al, 1987). This 
increased sensitivity to the pressor effects of AVP might 
represent either increased vascular sensitivity to AVP or 
diminished baroreflex function, or a combination of both, 
although the results in the tetraplegics (Poole et al,
1987) would favour the first alternative.
This study confirms that in diabetes mellitus, another 
disorder producing autonomic nerve damage, an enhanced 
pressor response to infused vasopressin may be seen. Six 
of the 8 DAN +ve and 2 of the DAN -ve patients showed 
marked pressor responses in excess of any of the normal 
subjects. Indeed, evidence from 24 hour ECG tape 
recording suggested that one of the DAN -ve patients had 
early autonomic damage not yet detectable by standard 
cardiovascular reflex tests.
t
It might be argued that as there were no statistically 
significant differences demonstrated between the blood 
pressure results of the two diabetic and the normal 
groups, the apparent pressor responses were not real. In 
fact, the problem with statistical analysis of this data 
arises because of the great variability in both diabetic 
groups, with apparent "responders" and "non-responders" in
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each group. When the results are examined on an 
individual rather than a group basis, it is clear that 
most, but not all, of those with cardiovascular reflex 
evidence of autonomic neuropathy, and a few of those with 
apparently normal cardiovascular reflexes, had enhanced 
blood pressure responses during AVP infusion. There is 
increasing evidence to suggest that early autonomic damage 
may. be present in diabetic subjects despite normal 
standard cardiovascular reflex tests (Ewing & Clarke,
1986). While, too, the mean age of the diabetic group 
with autonomic neuropathy was slightly higher than either 
the normal or the other diabetic group, I know of no 
evidence to suggest that pressor responsiveness to 
vasopressin increases with age.
The pressor response to infused AVP in the diabetic 
subjects is unlikely to be secondary to the loss of 
baroreflex activation, as the heart rate changed similarly 
in all three groups. It seems more probable that it 
represents increased sensitivity of the peripheral 
vasculature to vasopressin. Indeed, the fact that 
subjects with different types of autonomic nervous system 
involvement, whether associated with brainstem 
degeneration as in progressive autonomic failure (Williams 
et al, 1986), at cervical cord level as in tetraplegia 
(Poole et al, 1987), or peripherally as in diabetes, all 
respond to AVP infusion with marked pressor responses
120
suggest that sympathetic damage itself, at whatever level, 
results in an alteration of vascular vasopressin 
responses.
It is difficult to explain the waning of the pressor 
effect at the highest AVP infusion level, or the return of 
heart rate towards baseline values. It has, however, 
been noted by others during prolonged AVP infusion 
(Bennett & Gardiner, 1986), and might represent an 
adaptive neural mechanism causing less vasoconstriction, 
secondary release of some humoral dilator substance, or 
alternatively the recruitment of V2 receptors in different 
vascular beds. Indeed, when the V2 agonist DDAVP is 
infused in man, facial flushing occurs together with a 
fall in diastolic blood pressure (Williams, Lightman & 
Leadbetter, 1986).
Vasopressin has different pressor effects on different 
vascular beds. Activation of classical V^ receptors 
(Creba et al, 1983) causes vasoconstriction, while 
activation of V2 receptors (Roy et al, 1975) results in 
vasodilatation. Damage to the autonomic nervous system 
may alter both the sensitivity and the distribution of Vi 
and V2 receptors. There is some evidence for a 
vasopressin-like peptide in sympathetic neurones (Hanley 
et al, 1984), and autonomic nervous damage may result in 
"up regulation" of post synaptic vasopressin receptors.
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Finally, there is also evidence from 
noradrenaline/vasopressin interactions in man which 
suggests that decreased sympathetic activity alone results 
in increased dependence of vascular tone on circulating 
vasopressin (Ribiero et al, 1986). In addition to this 
some recent work is suggestive of AVP having a role in the 
maintenance of blood pressure in DAN +ve patients (Saad et 
al, , 1988). Clearly much of the work looking at AVP 
vascular responses in diabetics with autonomic neuropathy 
has yet to be done.
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Group mean (± SEM) plasma AVP concentrations during 
intravenous infusion of incremental doses of AVP in eight
diabetics with (o o), eight diabetics without (•---•)
autonomic neuropathy and six normal subjects ( ■ ).
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CHAPTER 7
GENERAL DISCUSSION AND CONCLUSIONS
In this thesis I have considered the effects of autonomic 
dysfunction, as encountered in diabetic autonomic 
neuropathy, in four separate results chapters, which have 
addressed aspects of control of heart rate, osmotic 
control of endogenous AVP release, the endogenous AVP 
responses to orthostasis and the cardiovascular responses 
to exogenous AVP administration. Each study has
therefore considered separate systems in isolation from 
one another in an attempt to test individual hypotheses. 
Such work forms the cornerstone of the scientific method, 
where the gathering of small pieces of information 
eventually add together in a jigsaw puzzle to provide the 
complete answer. In the presence of autonomic damage, 
the 'dynamic spheres of influence' (see introduction) 
which are brought into play help to maintain homeostasis, 
but are impossible to fully delineate. This work, in an 
attempt to broaden the knowledge of the effects of 
diabetic autonomic neuropathy in man, has tried to provide 
perhaps one or two jigsaw pieces to place in the puzzle.
The subjects studied in chapters 3 to, 6 represent the 
severe end of the spectrum of autonomic neuropathy caused 
by diabetes. They were categorised by well proven
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methods, drawn from a clinic with perhaps the best and 
longest experience of dealing with the condition, and were 
well characterised for other features of the disease, yet 
differences were observed in these studies between their 
responses and the responses previously observed in other 
forms of autonomic failure. The reasons for this will be 
addressed in this chapter.
Chapter three, using diabetics with autonomic neuropathy 
as a model analogous to that in denervated animals, 
considered whether or not the partial agonist activity of 
beta-adrenoreceptor blocking drugs could be directly shown 
in man, and whether the partial agonist activity in these 
drugs displayed cardioselectivity in man. In contrast to 
work in other forms of autonomic failure in man (Man in't 
Veld et al, 1981; 1982) heart rate was raised compared
with placebo in the drug with the greatest partial 
agonism, pindolol, although no direct effect of the drug 
was seen in terms of an increase in heart rate from 
baseline values. In addition to this, relative effects 
on heart rate proportional to the amount of PAA in the 
drugs were seen on 24 hour heart rate monitoring, whereby 
heart rate at night on pindolol was significantly higher 
than on placebo, no differences between placebo and 
epanolol were seen at night, and atenolol, with no PAA, 
lowered heart rate throughout the 24 hour period. 
Although there were changes observed, they were not as
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striking as those seen in PAF patients.
Using measurement of changes in physiological tremor as a 
model of B2 -adrenoceptor function, this work indeed showed 
that the selectivity of partial agonism in these drugs 
conforms to the cardioselectivity of the parent drug. By 
showing no change in physiological tremor after atenolol 
and. epanolol, the B^-selectivity of these drugs was 
confirmed. In contrast, a rise in physiological tremor 
was observed after dosing with pindolol, confirming that 
its partial agonism acts on both B^- and B2 -adrenoceptors. 
This study was the first to demonstrate this effect in 
man, although the denervated state is not necessary for 
its demonstration (McCaffrey et al, 1986).
There was evidence, from plasma glucose levels, that there 
may be some supersensitivity of B2 -adrenoceptors in the 
liver. Plasma glucose rose significantly from baseline 
after pindolol, and not after the other drugs. Again 
this effect had not previously been shown, but is in 
keeping with subsequent work on the effects of infused 
catecholamines in diabetics with autonomic neuropathy 
(Hilsted et al, 1987), the B2 ~partial agonism perhaps 
stimulating hepatic receptors and promoting 
glycogenolysis. No studies have to my knowledge been 
performed in diabetics without autonomic neuropathy to 
examine whether the metabolic effects of this drug are
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specific to DAN +ve subjects. v
Chapter four looked at osmotic stimulation of AVP 
secretion in a group of normal controls, a group of DAN - 
ve subjects, and for the first time in the human 
literature, diabetics with cardiovascular reflex evidence 
of autonomic neuropathy. Using the well established
technique of hypertonic saline infusion, the data obtained 
show that, consistent with other groups in whom autonomic 
dysfunction occurs (Williams et al, 1985; Poole et al,
1987), the hypothalamic-neurohypophyseal axis responds 
normally to an osmotic stimulus. There were, however, 
differences in the way blood pressure responded to 
hypertonic saline infusion. The mean blood pressure
changes calculated by AUC in the DAN +ve subjects during 
this study were not significantly different from the other 
two groups, in contrast to the studies of Williams et al
(1985) and Poole et al (1987) who in PAF subjects and 
tetraplegics respectively, found that blood pressure rose 
significantly during hypertonic saline infusion, and that 
the pressor response may in part be secondary to increased 
sensitivity of vascular receptors in the presence of 
the denervated state. It is interesting that one of the 
DAN +ve subjects had a 30 mmHg systolic blood pressure 
rise during the study, which may have been mediated by the 
same mechanism. The apparent lack of - group blood 
pressure change may also have other roots: either a type
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II error in the numbers in the study occurred, which is 
unlikely in view of the other positive data accrued; or 
the vascular Vi receptors, as with the B-adrenoceptors in 
chapter three, fail to 'upregulate' or increase their 
sensitivity, because denervation in diabetic autonomic 
neuropathy is not as 'complete' as in the other forms of 
autonomic dysfunction.
In addition to this, close correlations were seen between 
plasma osmolality and AVP, and plasma sodium and AVP. 
The abscissal intercept in the DAN -ve subjects was 
significantly lower than either DAN +ve or normal groups, 
but this is in keeping with the wide inter-individual 
variation already known to occur (Schrier et al, 1979), 
and no other firm conclusions can be drawn from the data.
Chapter five addressed the question of whether 
cardiovascular release of AVP is abnormal in diabetic 
autonomic neuropathy. The finding that, despite a major 
drop in blood pressure in the DAN +ve subjects, AVP levels 
did not increase relative to normals and DAN -ve subjects, 
is in keeping with the interruption of afferent pathways 
found in PAF subjects (Williams et al, 1985), but 
contrasts with work in tetraplegics (Sved et al, 1985; 
Poole et al, 1987), in whom an exaggerated rise in AVP 
levels was found. Tetraplegics have selective efferent 
loss of sympathetic pathways, and my study confirms that
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AVP response to head-up tilt tests the integrity of 
afferent pathways (Puritz et al, 1983; Poole et al, 1987; 
Zerbe et al, 1983).
Studies have confirmed this finding in DAN +ve subjects by 
using volume depletion (Grimaldi et al, 1985) and (less 
convincingly) orthostasis (Cignarelli et al, 1986).
The results in chapter five also confirm that in the 
absence of severe nephropathy (assessed by plasma 
creatinine levels), plasma renin release by orthostasis is 
normal in diabetic autonomic neuropathy, in keeping with 
the more recent literature (Hilsted et al, 1981; Winocour 
et al, 1986).
The significance of subnormal AVP release in diabetic 
autonomic neuropathy is as yet not fully explored. If 
denervation supersensitivity indeed exists, even low 
plasma levels of AVP may help to maintain blood pressure 
in the presence of orthostatic hypotension, and may have 
implications for treatment of this distressing condition 
in man. With the development of more specific Vi 
agonists (Manning & Sawyer, 1985) such therapeutic 
advances may be possible in the future.
In chapter six blood pressure responses were measured 
after infusion of physiological doses of AVP in normals,
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DAN -ve and DAN +ve subjects. There were no significant 
changes in blood pressure in the normal group. Six DAN 
+ve and two DAN -ve subjects showed marked rises in blood 
pressure during the infusion period, with maximum rises in 
mean blood pressure of 11 - 22 mmHg. The responses waned 
at the maximum AVP infusion rate in seven of the eight 
subjects. Despite the lack of statistical differences 
between the three groups, it is apparent that the 
'responders' clearly displayed abnormal sensitivity to the 
effects of AVP at physiological levels. If this is the 
correct interpretation of the data, the diabetics display 
increased pressor sensitivity to AVP in much the same way 
as PAF subjects and tetraplegics (Williams et al, 1986; 
Poole et al, 1987). Also, in keeping with the other 
groups of patients with autonomic dysfunction and in 
normal human subjects (Williams et al, 1986; Poole et al, 
1987; Ebert et al, 1986; Aylward et al, 1986), there 
appears to be little evidence that AVP influences 
baroreflexes significantly, as measured by the effects on 
heart rate. This is in contrast to the bulk of work in 
animals (Bennett & Gardiner, 1986).
Therefore, as in other groups of patients with both 
central and peripheral lesions affecting the autonomic 
nervous system, it appears that there is increased 
sensitivity to the pressor effects of infused vasopressin 
in diabetics with autonomic neuropathy. It now seems
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more likely that this effect may take place at the level 
of the blood vessels. With the discovery of the an AVP- 
like peptide (Hanley et al, 1984), it may be that this 
exerts post-ganglionic effects, and could show denervation 
supersensitivity as has been described for noradrenaline 
in PAF (Bannister et al, 1979). Indeed, a local
receptor-receptor interaction on the blood vessels would 
be consistent with the observation that AVP in sub-pressor 
doses potentiates the pressor action of catecholamines 
(Bartelstone & Nasmyth, 1965) and that decreased 
sympathetic tone results in increased dependence of 
vascular tone on circulating vasopressin (Ribiero et al, 
1986). As the specificity of and V2 agonists and 
antagonists is increased, it may be possible to use them 
to more fully dissect out the roles of vasopressin in 
diabetic autonomic neuropathy.
This thesis has attempted to address aspects of diabetic 
autonomic neuropathy by comparing and contrasting the 
results of studies presented within it with those in other 
forms of autonomic dysfunction. As the recognition has 
grown that the autonomic nervous system has moved from the 
perspective of anatomical simplicity, to one in which 
neuropeptide transmission, endocrine influences and other 
factors play an increasingly complex part, the concepts of 
denervation have changed. Complete deneryation is now 
becoming an untenable concept in man (Burnstock, Dhital &
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Alafaci, in press). Even when 'complete' cardiac 
denervation occurs by surgical section of the nerves, 
complex intracardiac reflexes are maintained (Kaye, 1984). 
As yet undiscovered neuropeptidergic mechanisms may 
persist in man, even when there is evidence that severe 
autonomic damage is present. The present state of
knowledge in this field is at present limited.
From the evidence I have presented, and with the 
comparisons with other groups of patients affected by 
autonomic dysfunction, it is clear that diabetics do 
display evidence of 'denervation' but that this may not 
manifest itself as floridly as in, for example, patients 
with progressive autonomic failure. Certainly, chapter 
three provides evidence that, unlike the vagotomised and 
catechol-depleted rat, the direct effects of partial 
agonism activity-containing beta adrenoreceptor blocking 
drugs cannot be shown in diabetic autonomic neuropathy, 
whereas in progressive autonomic failure they can. 
Chapter four shows for the first time that the 
hypothalamic-neurohypophyseal responses to osmotic 
stimulation are unaffected by autonomic neuropathy. 
Chapter five demonstrated an afferent defect in 
cardiovascular release of AVP in autonomic neuropathy, as 
is seen in other types of autonomic failure, and chapter 
six, suggests that vascular sensitivity to vasopressin is 
heightened in diabetics with autonomic failure, but as in
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chapter three, the responses are not so clear-cut as in 
other disorders of autonomic failure. Perhaps the 
concepts of denervation, mooted by Cannon in his 
posthumous monograph (Cannon & Rosenblueth, 1949), do 
still hold in most circumstances, but may have to be 
modified to take account of the complexities of 
neuropeptidergic and other influences on the autonomic 
nervous system.
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LIST
Ach
AUC
AVP
Beats min”1 
CV
DAN +ve
DAN -ve
HR
ISA
MAP/MBP 
ramHg 
mmol l”1 
mosm kg”1 
MSA 
ng
nmol I-1
NTS
OT
OVLT
PAA
PAF
pg ml”1 
pmol l”1 
pmol min”1kg 
PRA
OF ABBREVIATIONS
Acetylcholine
Area under the curve
Arginine vasopressin
Beats per minute
Coefficient(s) of variation
Diabetics with cardiovascular reflex test 
evidence of autonomic neuropathy
Diabetics without cardiovascular reflex test 
evidence of autonomic neuropathy
Heart rate
Intrinsic sympathomimetic activity
Mean arterial pressure/mean blood pressure
Millimetres of mercury
Millimoles per litre
Milliosmoles per kilogram
Multiple system atrophy
Nanograms per millilitre per hour
Nanomoles per litre
Nucleus of the tractus solitarius
Oxytocin
Organum vasculosum of the lamina terrainalis 
Partial agonist activity 
Progressive autonomic failure 
Picograms per millilitre 
Picomoles per litre 
Picomoles per minute per kilogram 
Plasma renin activity
-1
162
PVN Paraventricular nucleus
SON Supraoptic nucleus
TPR Total peripheral resistance
umol I-* Micromoles per litre
